[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 170
1. Vecchio R, Leanza V, Genovese F, Accardi M, Gelardi V, Intagliata E: Conservative laparoscopic treatment of a benign giant ovarian cyst in a young woman. J Laparoendosc Adv Surg Tech A; 2009 Oct;19(5):647-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Conservative laparoscopic treatment of a benign giant ovarian cyst in a young woman.
  • Giant ovarian cysts are very rare.
  • In this article, we describe the first case of complete laparoscopic enucleating of a giant serous cystoadenomyoma with preservation of residual ovarian parenchyma in an 18-year-old girl.
  • [MeSH-major] Cystadenoma, Serous / surgery. Laparoscopy / methods. Ovarian Cysts / surgery

  • MedlinePlus Health Information. consumer health - Ovarian Cysts.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19489679.001).
  • [ISSN] 1557-9034
  • [Journal-full-title] Journal of laparoendoscopic & advanced surgical techniques. Part A
  • [ISO-abbreviation] J Laparoendosc Adv Surg Tech A
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


2. Göçmen A, Atak T, Uçar M, Sanlikal F: Laparoscopy-assisted cystectomy for large adnexal cysts. Arch Gynecol Obstet; 2009 Jan;279(1):17-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: From January 1998 to October 2007, 46 women underwent laparoscopy-assisted surgery for large adnexal cysts whose maximum diameter were between 10 and 20 cm, radiologic and laboratory features suggestive of benign disease.
  • In all the patients, except one with borderline ovarian tumor, laparoscopy-assisted surgery was successful.
  • The surgical procedures performed were: ovarian and paraovarian cystectomy (n = 45), unilateral salpingo-oophorectomy, pelvic-paraaortic lymphadenectomy and omentectomy (n = 1).
  • Pathologic findings included serous cystadenoma (n = 26), mucinous cystadenoma (n = 7), dermoid (n = 6), endometriosis (n = 6), and borderline ovarian tumor (n = 1).
  • CONCLUSION: Laparoscopy-assisted surgery is feasible and safe for women with large benign adnexal cysts and result s in a short surgery time.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18431586.001).
  • [ISSN] 1432-0711
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


3. Timmerman D, Testa AC, Bourne T, Ferrazzi E, Ameye L, Konstantinovic ML, Van Calster B, Collins WP, Vergote I, Van Huffel S, Valentin L, International Ovarian Tumor Analysis Group: Logistic regression model to distinguish between the benign and malignant adnexal mass before surgery: a multicenter study by the International Ovarian Tumor Analysis Group. J Clin Oncol; 2005 Dec 1;23(34):8794-801
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Logistic regression model to distinguish between the benign and malignant adnexal mass before surgery: a multicenter study by the International Ovarian Tumor Analysis Group.
  • PURPOSE: To collect data for the development of a more universally useful logistic regression model to distinguish between a malignant and benign adnexal tumor before surgery.
  • The outcome measure was the histologic classification of excised tissues as malignant or benign.
  • RESULTS: Data from 1,066 patients recruited from nine European centers were included in the analysis; 800 patients (75%) had benign tumors and 266 (25%) had malignant tumors.
  • (1) personal history of ovarian cancer, (2) hormonal therapy, (3) age, (4) maximum diameter of lesion, (5) pain, (6) ascites, (7) blood flow within a solid papillary projection, (8) presence of an entirely solid tumor, (9) maximal diameter of solid component, (10) irregular internal cyst walls, (11) acoustic shadows, and (12) a color score of intratumoral blood flow.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / blood. CA-125 Antigen / blood. Cystadenoma, Mucinous / classification. Cystadenoma, Mucinous / diagnosis. Cystadenoma, Mucinous / surgery. Cystadenoma, Papillary / classification. Cystadenoma, Papillary / diagnosis. Cystadenoma, Papillary / surgery. Cystadenoma, Serous / classification. Cystadenoma, Serous / diagnosis. Cystadenoma, Serous / surgery. Diagnosis, Differential. Female. Humans. Logistic Models. Middle Aged. Multivariate Analysis. Ovarian Cysts / classification. Ovarian Cysts / diagnosis. Ovarian Cysts / surgery. Ovarian Neoplasms / classification. Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / surgery. Ovariectomy. Prospective Studies. Reproducibility of Results. Sensitivity and Specificity

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16314639.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen
  •  go-up   go-down


Advertisement
4. Worley MJ Jr, Landen CN, Slomovitz BM, Malpica A, Palla SL, Ramirez PT: Expression of the retinoblastoma-related gene Rb2/p130 in the pathogenesis of serous carcinoma of the ovary. Appl Immunohistochem Mol Morphol; 2010 Dec;18(6):509-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of the retinoblastoma-related gene Rb2/p130 in the pathogenesis of serous carcinoma of the ovary.
  • OBJECTIVE: The purpose of this study was to evaluate the immunohistochemical Rb2/p130 expression in a series of benign, borderline, and malignant ovarian tumors.
  • Frequencies and percents were calculated for variables by each of the 5 disease stage groups in increasing severity and again for the disease stage groups collapsed into benign (serous cystadenoma or endosalpingosis), low-grade [serous borderline tumors (SBT) or low-grade serous carcinoma (LGSC)] and high-grade serous carcinoma.
  • RESULTS: There was no loss of expression in benign serous cystadenomas (0/18).
  • There was a significant difference in the expression during the progression from cystadenoma to SBT to LGSC.
  • CONCLUSIONS: Loss of Rb2/p130 expression is a rare event in benign cystadenoma.

  • Genetic Alliance. consumer health - Retinoblastoma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20661130.001).
  • [ISSN] 1533-4058
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Lectins; 0 / Membrane Glycoproteins; 0 / Phytohemagglutinins; 0 / Retinoblastoma-Like Protein p130; 0 / erythroagglutinating phytohemagglutinin; EC 2.4.1.- / N-Acetylglucosaminyltransferases; V956696549 / Acetylglucosamine
  •  go-up   go-down


5. Auner V, Sehouli J, Oskay-Oezcelik G, Horvat R, Speiser P, Zeillinger R: ABC transporter gene expression in benign and malignant ovarian tissue. Gynecol Oncol; 2010 May;117(2):198-201
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ABC transporter gene expression in benign and malignant ovarian tissue.
  • Gene expression data from individual transporters in ovarian cancer tissue is contradictory and also scarce for some of them.
  • RNA levels of a panel of ABC transporters were collected and analyzed to get a more detailed overview which transporters are of importance in resistance to chemotherapeutic agents in ovarian carcinoma.
  • METHODS: Real-time PCR was used to determine RNA expression levels of 9 ABC transporters in 50 benign tissue samples and 50 recurrent ovarian cancer samples.
  • RESULTS: Gene expression of four transporters (ABCC1, ABCC2, ABCC3, and ABCB3) was significantly elevated in recurrent cancer lesions compared to benign tissue.
  • Expression levels of these 4 ABC transporters were further analyzed in primary ovarian cancer lesions.
  • Changes in gene expression between benign samples and primary lesions were minor and not relevant.
  • CONCLUSIONS: Four of the examined ABC transporters are likely to play a role in the MDR of ovarian carcinoma.
  • The thesis that MDR in ovarian cancer is acquired through therapy itself and not present ab initio is supported by these findings.
  • [MeSH-major] ATP-Binding Cassette Transporters / biosynthesis. Ovarian Neoplasms / genetics
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carboplatin / administration & dosage. Cyclophosphamide / administration & dosage. Cystadenoma / genetics. Cystadenoma / metabolism. Cystadenoma / pathology. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Female. Gene Expression. Humans. Neoplasm Recurrence, Local / genetics. Neoplasm Recurrence, Local / metabolism. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Paclitaxel / administration & dosage. ROC Curve. Up-Regulation

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 Elsevier Inc. All rights reserved.
  • (PMID = 19922990.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ATP-Binding Cassette Transporters; 0W860991D6 / Deoxycytidine; 8N3DW7272P / Cyclophosphamide; B76N6SBZ8R / gemcitabine; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


6. Petros M, Koliba P, Sevcík L, Curík R: [Giant benign mucinous cystadenoma of both ovaries in early puerperium: case report and review of literature]. Ceska Gynekol; 2005 Mar;70(2):156-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Giant benign mucinous cystadenoma of both ovaries in early puerperium: case report and review of literature].
  • [Transliterated title] Obrovský benigní mucinózní kystadenom obou ovarií v casném puerperiu: Popis prípadu a prehled literatury.
  • OBJECTIVE: A case report of giant bilateral benign cystadenoma after vaginal delivery.
  • Subsequent histological examination revealed a benign mucinous cystadenoma.
  • CONCLUSION: A case of giant mucinous cystadenoma is presented with clinical and pathological details.
  • An ovarian cystadenoma was the cause of an acute abdomen in puerperium and led to clinical and therapeutic disconcerment.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Postpartum Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15918273.001).
  • [ISSN] 1210-7832
  • [Journal-full-title] Ceska gynekologie
  • [ISO-abbreviation] Ceska Gynekol
  • [Language] CZE
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Czech Republic
  • [Number-of-references] 14
  •  go-up   go-down


7. Zorina VN, Kozlov IG, Tret'iakova TV, Promzeleva NV, Bazhenova LG, Zorina RM, Riabicheva TG, Zorin NA: [Various acute phase reactants in different types of proliferative diseases of the uterine appendages]. Klin Lab Diagn; 2009 Oct;(10):16-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The authors examined serum in patients with ovarian cancer (OC; a disseminated process), ovarian cystadenoma (OCA), or external endometriosis (EM) before treatment and in apparently healthy females (a control) for the content of some acute-phase proteins and cytokines to clarify the specific features of changes in their concentrations in relation to the type of the proliferative process.
  • [MeSH-major] Acute-Phase Proteins / analysis. Cystadenoma / blood. Cytokines / blood. Endometriosis / blood. Ovarian Neoplasms / blood
  • [MeSH-minor] Biomarkers / blood. Female. Humans. Ovarian Diseases / blood

  • MedlinePlus Health Information. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20000108.001).
  • [ISSN] 0869-2084
  • [Journal-full-title] Klinicheskaia laboratornaia diagnostika
  • [ISO-abbreviation] Klin. Lab. Diagn.
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Acute-Phase Proteins; 0 / Biomarkers; 0 / Cytokines
  •  go-up   go-down


8. Ye F, Li Y, Hu Y, Zhou C, Hu Y, Chen H: Stage-specific embryonic antigen 4 expression in epithelial ovarian carcinoma. Int J Gynecol Cancer; 2010 Aug;20(6):958-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stage-specific embryonic antigen 4 expression in epithelial ovarian carcinoma.
  • METHODS: In this study, we investigated the expression of SSEA-4 in 479 cases of various degrees of ovarian epithelial lesions by immunohistochemistry, consisting of 45 normal ovarian epithelia, 110 benign serous ovarian cystadenomas, 68 borderline serous ovarian cystadenomas, 104 invasive serous ovarian carcinomas, 64 benign serous mucinous cystadenomas, 48 borderline mucinous ovarian cystadenomas, and 40 invasive mucinous carcinomas.
  • RESULTS: The expression of SSEA-4 was found to be increased from normal epithelium to benign cystadenoma and to borderline cystadenoma and adenocarcinoma in both serous and mucinous group.
  • CONCLUSIONS: We therefore proposed that SSEA-4 may play a role during the oncogenesis of epithelial ovarian carcinoma and posses a tumor suppressor effect during malignancy promotion.
  • It could be a potential therapy target in patients with epithelial ovarian carcinoma.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Carcinoma / immunology. Carcinoma / pathology. Ovarian Neoplasms / immunology. Ovarian Neoplasms / pathology. Stage-Specific Embryonic Antigens / metabolism
  • [MeSH-minor] Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Adult. Aged. Biopsy, Needle. Cohort Studies. Cystadenocarcinoma, Serous / metabolism. Cystadenocarcinoma, Serous / pathology. Cystadenoma, Mucinous / metabolism. Cystadenoma, Mucinous / pathology. Cystadenoma, Serous / metabolism. Cystadenoma, Serous / pathology. Disease Progression. Female. Humans. Immunohistochemistry. Middle Aged. Neoplasm Staging. Prognosis. Reference Values. Sensitivity and Specificity. Statistics, Nonparametric. Tissue Embedding

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20683402.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Stage-Specific Embryonic Antigens; 0 / stage-specific embryonic antigen-4
  •  go-up   go-down


9. Zagorianakou N, Stefanou D, Makrydimas G, Zagorianakou P, Briasoulis E, Karavasilis V, Pavlidis N, Agnantis NJ: Clinicopathological study of metallothionein immunohistochemical expression, in benign, borderline and malignant ovarian epithelial tumors. Histol Histopathol; 2006 04;21(4):341-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological study of metallothionein immunohistochemical expression, in benign, borderline and malignant ovarian epithelial tumors.
  • This study examined the immunohistochemical expression of MTs in benign, borderline and malignant tumors of ovarian surface epithelium and the possible correlations with clinicopathological parameters and survival.
  • A total of 87 cases with diagnosis of ovarian surface epithelial tumors were included.
  • Specifically, 21 cases of benign cystadenomas (11 serous and 10 mucinous), 14 borderline (low malignant potential tumors, 8 mucinous and 6 serous) and 52 cases of ovarian cancer were analysed.
  • A statistically significant correlation was found between the expression of MT in cancer cases and benign tumors (p < 0.0001) and cancer cases and borderline tumors p = 0.003.
  • There was no correlation of MT overexpression with survival in the small number of ovarian carcinoma patients where it was analysed.
  • MT constitutes a marker that characterizes aggressiveness and a high malignant potential in ovarian epithelial tumors.
  • In diagnostic problems MT may help distinguish between benign, borderline and malignant tumors.
  • [MeSH-major] Carcinoma / chemistry. Metallothionein / analysis. Ovarian Neoplasms / chemistry
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Cell Differentiation / genetics. Cell Proliferation. Cystadenoma, Mucinous / chemistry. Cystadenoma, Mucinous / diagnosis. Cystadenoma, Mucinous / pathology. Cystadenoma, Serous / chemistry. Cystadenoma, Serous / diagnosis. Cystadenoma, Serous / pathology. Diagnosis, Differential. Disease Progression. Female. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Middle Aged. Tumor Suppressor Protein p53 / analysis. Tumor Suppressor Protein p53 / genetics. Tumor Suppressor Protein p53 / physiology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16437378.001).
  • [ISSN] 1699-5848
  • [Journal-full-title] Histology and histopathology
  • [ISO-abbreviation] Histol. Histopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Tumor Suppressor Protein p53; 9038-94-2 / Metallothionein
  •  go-up   go-down


10. Alobaid AS: Mucinous cystadenoma of the ovary in a 12-year-old girl. Saudi Med J; 2008 Jan;29(1):126-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucinous cystadenoma of the ovary in a 12-year-old girl.
  • Benign mucinous cystadenomas MCA are rare benign neoplasms in the pediatric age group.
  • We present a 12-year-old patient that had a huge mass arising from the left ovary causing bilateral hydronephrosis and renal insufficiency.
  • The final pathology revealed a benign MCA.
  • [MeSH-major] Cystadenoma, Mucinous / diagnosis. Ovarian Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18176687.001).
  • [ISSN] 0379-5284
  • [Journal-full-title] Saudi medical journal
  • [ISO-abbreviation] Saudi Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Saudi Arabia
  •  go-up   go-down


11. Shi HR, Zhang RT: [Expression and significance of P53, P21WAF1 and CDK1 proteins in epithelial ovarian cancer]. Ai Zheng; 2009 Aug;28(8):882-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression and significance of P53, P21WAF1 and CDK1 proteins in epithelial ovarian cancer].
  • This study was to investigate the expression and significance of P53, P21WAF1 and CDK1 proteins in epithelial ovarian cancer.
  • METHODS: The expression of P53, P21WAF1 and CDK1 proteins in 20 specimens of normal ovarian tissues, 20 specimens of benign epithelial ovarian tumor and 76 specimens of epithelial ovarian cancer was detected by immunohistochemistry.
  • Their correlations to the clinicopathologic characteristics of epithelial ovarian cancer and their interrelationships were analyzed.
  • RESULTS: Significant differences were noted in the positive rates of P53, P21WAF1 and CDK1 proteins between epithelial ovarian cancer and normal ovarian tissues, benign ovarian tumors (P < 0.05).
  • In epithelial ovarian cancer, up-regulation of P53 protein was associated with advanced FIGO stage and poor differentiation; down-regulation of P21WAF1 protein was associated with advanced FIGO stage; CDK1 showed no association with any clinicopathologic factors.
  • CONCLUSIONS: P53 protein is related to the malignancy of epithelial ovarian cancer, P53 and P21WAF1 protein may be related to the malignant development of epithelial ovarian cancer.
  • CDK1 detection may be helpful in the early diagnosis of epithelial ovarian cancer.
  • [MeSH-major] CDC2 Protein Kinase / metabolism. Cyclin-Dependent Kinase Inhibitor p21 / metabolism. Cystadenocarcinoma, Mucinous / metabolism. Cystadenocarcinoma, Serous / metabolism. Ovarian Neoplasms / metabolism. Tumor Suppressor Protein p53 / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Cystadenoma, Mucinous / metabolism. Cystadenoma, Mucinous / pathology. Cystadenoma, Serous / metabolism. Cystadenoma, Serous / pathology. Female. Humans. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Ovary / metabolism. Ovary / pathology. Young Adult

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19664338.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDKN1A protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53; EC 2.7.11.22 / CDC2 Protein Kinase
  •  go-up   go-down


12. Stankovic ZB, Djukic MK, Savic D, Lukac BJ, Djuricic S, Sedlecki K, Zdravkovic D: Pre-operative differentiation of pediatric ovarian tumors: morphological scoring system and tumor markers. J Pediatr Endocrinol Metab; 2006 Oct;19(10):1231-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pre-operative differentiation of pediatric ovarian tumors: morphological scoring system and tumor markers.
  • OBJECTIVE: To investigate the importance of morphological scoring systems in differentiation of ovarian tumors in childhood.
  • METHODS: Morphological assessment using DePriest's index was performed for all patients with histopathological confirmation of ovarian tumor, with evaluation of tumor markers, from January 1997.
  • RESULTS: Fifty-three girls (age range 13 months to 19 years) were surgically treated for 59 ovarian tumors, including six bilateral.
  • All lesions with cystic appearance on ultrasonography were benign, 23 of 35 semisolid, and four of ten solid tumors were also benign.
  • Sensitivity, positive predictive value and accuracy by DePriest's and Ueland's indexes for benign tumors (score <7) were: 0.88, 0.79; 0.89; and 0.94, 0.84; 0.93; respectively.
  • CONCLUSION: Ultrasonographic assessment with morphological analysis recommended by DePriest and Ueland is a very useful procedure for differentiating benign from malignant ovarian tumors in children.
  • [MeSH-major] Ovarian Neoplasms / pathology
  • [MeSH-minor] Adolescent. CA-125 Antigen / blood. Cell Differentiation / physiology. Child. Chorionic Gonadotropin / blood. Cystadenoma / blood. Cystadenoma / pathology. Cystadenoma / surgery. Cystadenoma / ultrasonography. Female. Fibroma / blood. Fibroma / pathology. Fibroma / surgery. Fibroma / ultrasonography. Gonadoblastoma / blood. Gonadoblastoma / pathology. Gonadoblastoma / surgery. Gonadoblastoma / ultrasonography. Humans. Infant. L-Lactate Dehydrogenase / blood. Predictive Value of Tests. Preoperative Care. Sensitivity and Specificity. Teratoma / blood. Teratoma / pathology. Teratoma / surgery. Teratoma / ultrasonography. alpha-Fetoproteins / metabolism

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17172084.001).
  • [ISSN] 0334-018X
  • [Journal-full-title] Journal of pediatric endocrinology & metabolism : JPEM
  • [ISO-abbreviation] J. Pediatr. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CA-125 Antigen; 0 / Chorionic Gonadotropin; 0 / alpha-Fetoproteins; EC 1.1.1.27 / L-Lactate Dehydrogenase
  •  go-up   go-down


13. Hackethal A, Brueggmann D, Turovets M, Bassaly B, Stein A, Gerber EL, Muenstedt K: Removal of enormous bilateral mucinous cystadenomas of the ovaries with abdominal plastic reconstruction. Arch Gynecol Obstet; 2009 Jan;279(1):65-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Bilateral mucinous cystadenoma of the ovary are extremely rare.
  • These tumors are benign and might lead to abdominal distension, if no secondary symptoms occur and patient delay the consultation of physicians.
  • Tumor excision was initiated and final histology revealed bilateral mucinous cystadenoma of the ovaries.
  • [MeSH-major] Cystadenoma, Mucinous / surgery. Ovarian Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18386030.001).
  • [ISSN] 1432-0711
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


14. Swamy GG, Satyanarayana N: Clinicopathological analysis of ovarian tumors--a study on five years samples. Nepal Med Coll J; 2010 Dec;12(4):221-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological analysis of ovarian tumors--a study on five years samples.
  • Ovarian neoplasms have become increasingly important not only because of the large variety of neoplastic entities but more because they have gradually increased the mortality rate due to female genital cancers.
  • A total of 120 cases of ovarian tumors were studied at the Department of Pathology, Konaseema Institute of Medical Sciences, Amalapuram, India, during the period of March 2005 to March 2010, to find out frequency of different histological patterns of ovarian tumors at Konaseema Region.
  • Among 120 cases, majority 86 (71.6%) were benign, but alarming number 30 (25.0%) were malignant, remaining 4 cases were borderline.
  • The commonest benign tumor was serous cyst adenoma, while; the commonest malignant tumors were granulosa cell tumor and endometrial carcinoma.
  • Epithelial tumors were commonest variety of ovarian tumors followed by germ cell tumors.
  • [MeSH-major] Ovarian Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Cystadenoma, Serous / pathology. Epithelium / surgery. Female. Granulosa Cell Tumor / pathology. Humans. Middle Aged. Young Adult

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21744762.001).
  • [Journal-full-title] Nepal Medical College journal : NMCJ
  • [ISO-abbreviation] Nepal Med Coll J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Nepal
  •  go-up   go-down


15. Raiga J, Djafer R, Benoit B, Treisser A: [Management of ovarian cysts]. J Chir (Paris); 2006 Sep-Oct;143(5):278-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Management of ovarian cysts].
  • Ovarian cysts occur frequently in women of reproductive age.
  • The most common are serous and mucinous cystadenomas which arise from the epithelial wall of the ovary, endometriomas which arise in the setting of pelvic endometriosis, and dermoid cysts which arise from the germinal cells of the ovary.
  • Pelvic laparoscopy is the surgical approach of choice for the treatment of non-functional benign ovarian cysts.
  • Conservative treatment to shell out the cyst and preserve functional ovarian tissue should be reserved for women desirous of future pregnancies.
  • The risk of ovarian cancer remains a major preoccupation of the surgeon.
  • This article describes the diagnostic techniques which allow a laparoscopic approach to presumably benign cysts and discusses surgical techniques specifically adapted to their different histologic nature of ovarian cysts.
  • [MeSH-major] Ovarian Cysts / surgery
  • [MeSH-minor] Biomarkers, Tumor / analysis. Cystadenoma, Mucinous / classification. Cystadenoma, Mucinous / surgery. Cystadenoma, Serous / classification. Cystadenoma, Serous / surgery. Dermoid Cyst / classification. Dermoid Cyst / surgery. Endometriosis / classification. Endometriosis / surgery. Female. Humans. Laparoscopy / contraindications. Laparoscopy / methods. Laparotomy. Magnetic Resonance Imaging. Ovarian Neoplasms / classification. Ovarian Neoplasms / surgery. Ultrasonography, Doppler

  • MedlinePlus Health Information. consumer health - Ovarian Cysts.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17185953.001).
  • [ISSN] 0021-7697
  • [Journal-full-title] Journal de chirurgie
  • [ISO-abbreviation] J Chir (Paris)
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


16. Exacoustos C, Romanini ME, Rinaldo D, Amoroso C, Szabolcs B, Zupi E, Arduini D: Preoperative sonographic features of borderline ovarian tumors. Ultrasound Obstet Gynecol; 2005 Jan;25(1):50-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative sonographic features of borderline ovarian tumors.
  • OBJECTIVE: To determine the sonographic findings that distinguish borderline ovarian tumors (BOT) from both benign and invasive malignant tumors, thus allowing conservative treatment and laparoscopic management of these tumors.
  • We compared these findings with those of 337 patients with benign ovarian tumors and those of 82 patients with invasive malignant ovarian tumors.
  • The presence of papillae, defined as a small number of solid tissue projections, 1-15 mm in height and 1-10 mm in width (base) and length (base), into the cyst cavity from the cyst wall, was significantly more frequent in BOT (48%) than it was in benign (4%) and invasive (4%) malignant tumors.
  • Intracystic solid tissue (> 15 mm in height or > 10 mm in width or length) was observed in 48% of invasive malignant masses but in only 18% of BOT and in 7% of benign tumors (P < 0.001).
  • [MeSH-major] Ovarian Neoplasms / surgery. Ovarian Neoplasms / ultrasonography. Preoperative Care / methods
  • [MeSH-minor] Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / surgery. Adenocarcinoma, Mucinous / ultrasonography. Adolescent. Adult. Aged. Aged, 80 and over. Child. Cystadenoma, Serous / pathology. Cystadenoma, Serous / surgery. Cystadenoma, Serous / ultrasonography. Diagnosis, Differential. Female. Humans. Middle Aged. Neoplasm Invasiveness. Postmenopause. Premenopause. Retrospective Studies. Sensitivity and Specificity. Ultrasonography, Doppler / methods

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2004 ISUOG.
  • (PMID = 15619309.001).
  • [ISSN] 0960-7692
  • [Journal-full-title] Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology
  • [ISO-abbreviation] Ultrasound Obstet Gynecol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


17. Capar M, Balci O, Acar A, Colakoglu MC: Management of ovarian cysts by laparoscopic extracorporeal approach using single ancillary trocar. Taiwan J Obstet Gynecol; 2009 Dec;48(4):380-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of ovarian cysts by laparoscopic extracorporeal approach using single ancillary trocar.
  • OBJECTIVE: This prospective study aimed to evaluate an alternative laparoscopic extracorporeal approach for the treatment of benign ovarian cysts.
  • MATERIALS AND METHODS: The initial study population included 243 patients diagnosed with benign ovarian masses.
  • Homeostasis was performed and the ovary was then released.
  • The pathologies of the cysts were simple cyst in 86 cases, endometrioma in 68, serous cyst in 57, mucinous cyst in eight and borderline in one.
  • [MeSH-major] Laparoscopy / methods. Ovarian Cysts / surgery. Surgical Instruments
  • [MeSH-minor] Adenocarcinoma, Mucinous / surgery. Adult. Cystadenoma, Serous / surgery. Endometriosis / surgery. Female. Humans. Laparotomy. Ovarian Neoplasms / surgery. Patient Satisfaction. Postoperative Complications. Prospective Studies

  • MedlinePlus Health Information. consumer health - Ovarian Cysts.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Taiwan J Obstet Gynecol. 2009 Dec;48(4):333-4 [20045752.001]
  • (PMID = 20045759.001).
  • [ISSN] 1875-6263
  • [Journal-full-title] Taiwanese journal of obstetrics & gynecology
  • [ISO-abbreviation] Taiwan J Obstet Gynecol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] China
  •  go-up   go-down


18. Timofeev J, Galgano MT, Stoler MH, Lachance JA, Modesitt SC, Jazaeri AA: Appendiceal pathology at the time of oophorectomy for ovarian neoplasms. Obstet Gynecol; 2010 Dec;116(6):1348-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Appendiceal pathology at the time of oophorectomy for ovarian neoplasms.
  • OBJECTIVE: To investigate the prevalence of appendiceal pathology in women undergoing surgery for a suspected ovarian neoplasm and the predictive value of intraoperative findings to determine the need for appendectomy at the time of surgery.
  • Observations were stratified based on the nature (benign, borderline, or malignant) and histology (serous compared with mucinous) of the ovarian neoplasm, frozen compared with final pathological diagnosis, and the gross appearance of the appendix.
  • The highest rates of coexisting appendiceal pathology were associated with serous ovarian cancers (94.4% of grossly abnormal and 35.3% of normal appendices) and ovarian tumors suspected to be of primary gastrointestinal origin (83.3% grossly abnormal and 60.0% normal appendices harbored coexisting mucinous neoplasms).
  • Linear regression analysis revealed that appearance of the appendix and frozen section diagnosis of the ovarian pathology were statistically significant predictors of coexisting appendiceal pathology, but the latter was more important.
  • CONCLUSION: The prevalence of coexisting, clinically significant appendiceal pathology is low with a frozen section diagnosis of serous or mucinous cystadenoma.
  • Appendectomy is recommended when frozen section diagnosis is mucinous or serous ovarian carcinoma, borderline tumor or metastatic carcinoma of suspected gastrointestinal origin.
  • [MeSH-major] Appendectomy. Ovarian Neoplasms / surgery. Ovariectomy

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21099601.001).
  • [ISSN] 1873-233X
  • [Journal-full-title] Obstetrics and gynecology
  • [ISO-abbreviation] Obstet Gynecol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Wang XY, Dai JR, Zhu Z, Zhao YF, Zhou CW: [CT features of ovarian Brenner tumor and a report of 9 cases]. Zhonghua Zhong Liu Za Zhi; 2010 May;32(5):359-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [CT features of ovarian Brenner tumor and a report of 9 cases].
  • OBJECTIVE: In order to improve the preoperative diagnostic accuracy, the computed tomographic (CT) features of ovarian Brenner tumor were described and analyzed.
  • There were 8 benign lesions and 1 borderline lesion.
  • Among the nine cases, 5 were benign tumors with uniform structure, 3 were benign tumors accompanied with other pathological components, and 1 was borderline tumor.
  • On the CT images, the 5 uniform benign lesions showed to be solid tumor of low density (lower than that of muscle) or with small cyst inside, two of the 5 lesions had calcification, and other 2 lesions showed slightly heterogeneous enhancement after enhanced scanning.
  • The 3 benign Brenner tumors accompanied with other pathological structures were solid-cystic or cystic, with a clear demarcation of solid and cystic components.
  • CONCLUSION: Ovarian Brenner tumors are usually unilateral and often accompanied with other type of tumor components.
  • After enhancing, a benign Brenner tumor is slightly enhanced, while the borderline one is moderately/highly enhanced.
  • [MeSH-major] Brenner Tumor / radiography. Ovarian Neoplasms / radiography. Tomography, Spiral Computed / methods
  • [MeSH-minor] Aged. Carcinoma, Transitional Cell / diagnosis. Cystadenoma, Mucinous / radiography. Cystadenoma, Serous / diagnosis. Diagnosis, Differential. Female. Humans. Middle Aged. Ovary / radiography. Sex Cord-Gonadal Stromal Tumors / diagnosis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20723434.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


20. Ylisaukko-oja SK, Cybulski C, Lehtonen R, Kiuru M, Matyjasik J, Szymañska A, Szymañska-Pasternak J, Dyrskjot L, Butzow R, Orntoft TF, Launonen V, Lubiñski J, Aaltonen LA: Germline fumarate hydratase mutations in patients with ovarian mucinous cystadenoma. Eur J Hum Genet; 2006 Jul;14(7):880-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Germline fumarate hydratase mutations in patients with ovarian mucinous cystadenoma.
  • HLRCC is characterized by benign leiomyomas of the skin and the uterus, renal cell carcinoma, and uterine leiomyosarcoma.
  • FH germline mutations were screened from 89 patients with RCC, skin leiomyomas or ovarian tumors.
  • Subsequently, 13 ovarian and 48 bladder carcinomas were analyzed for somatic FH mutations.
  • Two patients diagnosed with ovarian mucinous cystadenoma (two out of 33, 6%) were found to be FH germline mutation carriers.
  • These results suggest that benign ovarian tumors may be associated with HLRCC.
  • [MeSH-major] Cystadenoma, Mucinous / genetics. Fumarate Hydratase / genetics. Germ-Line Mutation. Neoplastic Syndromes, Hereditary / genetics. Ovarian Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16639410.001).
  • [ISSN] 1018-4813
  • [Journal-full-title] European journal of human genetics : EJHG
  • [ISO-abbreviation] Eur. J. Hum. Genet.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 4.2.1.2 / Fumarate Hydratase
  •  go-up   go-down


21. Tannuri AC, Tannuri U, Gibelli NE, Romão RL: Surgical treatment of hepatic tumors in children: lessons learned from liver transplantation. J Pediatr Surg; 2009 Nov;44(11):2083-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ten children presented with other malignant tumors-3 undifferentiated sarcomas, 2 hepatocellular carcinomas, 2 fibrolamellar hepatocellular carcinomas, a rhabdomyosarcoma, an immature ovarian teratoma, and a single neuroblastoma.
  • Six children had benign tumors-4 mesenchymal hamartoma, 1 focal nodular hyperplasia, and a mucinous cystadenoma.


22. Levanon K, Crum C, Drapkin R: New insights into the pathogenesis of serous ovarian cancer and its clinical impact. J Clin Oncol; 2008 Nov 10;26(32):5284-93
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] New insights into the pathogenesis of serous ovarian cancer and its clinical impact.
  • One such dogma is the adenoma-carcinoma sequence and that a multistep accumulation of genetic alterations is required for transformation from a benign to a neoplastic tissue.
  • Until fairly recently, high-grade serous ovarian carcinoma seemed to be one of the only known deviants of these concepts.
  • In this article, we discuss the emergence of the fallopian tube fimbria as a field of origin for high-grade serous carcinomas and present a binary model of ovarian cancer pathogenesis that takes into consideration prior epidemiologic, morphologic, and genetic data.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Gynecol Pathol. 1997 Jul;16(3):250-5 [9421091.001]
  • [Cites] Cancer Res. 1998 May 15;58(10):2095-7 [9605750.001]
  • [Cites] J Natl Cancer Inst. 1998 Dec 2;90(23):1774-86 [9839517.001]
  • [Cites] Hum Reprod. 1998 Nov;13(11):3114-20 [9853867.001]
  • [Cites] Gynecol Obstet Invest. 1999;47(1):45-51 [10026026.001]
  • [Cites] Hum Pathol. 1999 Feb;30(2):151-7 [10029442.001]
  • [Cites] Gynecol Oncol. 1999 Mar;72(3):437-42 [10053122.001]
  • [Cites] J Natl Cancer Inst. 1999 Apr 7;91(7):626-8 [10203282.001]
  • [Cites] Hum Reprod. 1999 Jan;14(1):162-6 [10374114.001]
  • [Cites] Exp Mol Pathol. 1999 Jun;66(2):163-9 [10409445.001]
  • [Cites] J Natl Cancer Inst. 1999 Sep 1;91(17):1459-67 [10469746.001]
  • [Cites] Surg Gynecol Obstet. 1951 Sep;93(3):327-30 [14866716.001]
  • [Cites] Obstet Gynecol Surv. 1961 Apr;16:209-26 [13749597.001]
  • [Cites] Am J Obstet Gynecol. 1950 Jan;59(1):58-67, illust [15399626.001]
  • [Cites] N Engl J Med. 2004 Dec 9;351(24):2519-29 [15590954.001]
  • [Cites] Cancer Res. 2005 Mar 15;65(6):2162-9 [15781627.001]
  • [Cites] Adv Cancer Res. 2005;93:159-87 [15797447.001]
  • [Cites] Nature. 2005 Apr 14;434(7035):864-70 [15829956.001]
  • [Cites] Nature. 2005 Apr 14;434(7035):907-13 [15829965.001]
  • [Cites] Cancer. 1999 Oct 15;86(8):1544-50 [10526284.001]
  • [Cites] Hum Reprod. 2000 Jul;15(7):1597-603 [10875873.001]
  • [Cites] J Clin Oncol. 2000 Jul;18(14):2728-32 [10894872.001]
  • [Cites] Cancer. 2000 Jul 15;89(2):383-90 [10918170.001]
  • [Cites] Gynecol Oncol. 2000 Sep;78(3 Pt 1):278-87 [10985881.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Dec 1;48(5):1427-31 [11121643.001]
  • [Cites] Gynecol Oncol. 2001 Feb;80(2):176-80 [11161856.001]
  • [Cites] Endocr Rev. 2001 Apr;22(2):255-88 [11294827.001]
  • [Cites] Lancet. 2001 May 12;357(9267):1467-70 [11377596.001]
  • [Cites] Histopathology. 2001 May;38(5):481-2 [11422490.001]
  • [Cites] Am J Surg Pathol. 2001 Oct;25(10):1283-9 [11688463.001]
  • [Cites] Cancer Res. 2001 Nov 15;61(22):8247-55 [11719457.001]
  • [Cites] Ital J Anat Embryol. 2001;106(2 Suppl 2):263-76 [11732586.001]
  • [Cites] J Pathol. 2001 Nov;195(4):451-6 [11745677.001]
  • [Cites] Am J Surg Pathol. 2002 Feb;26(2):171-8 [11812938.001]
  • [Cites] N Engl J Med. 2002 May 23;346(21):1609-15 [12023992.001]
  • [Cites] J Natl Cancer Inst. 2002 Sep 18;94(18):1365-72 [12237282.001]
  • [Cites] Int J Gynecol Cancer. 2002 Nov-Dec;12(6):691-703 [12445245.001]
  • [Cites] Nature. 2002 Dec 19-26;420(6917):860-7 [12490959.001]
  • [Cites] Int J Cancer. 2003 Mar 20;104(2):228-32 [12569579.001]
  • [Cites] J Clin Oncol. 2003 Mar 15;21(6):1035-43 [12637468.001]
  • [Cites] J Natl Cancer Inst. 2003 Mar 19;95(6):484-6 [12644542.001]
  • [Cites] Nature. 2003 Mar 20;422(6929):322-6 [12646923.001]
  • [Cites] Am J Surg Pathol. 2003 Jun;27(6):725-36 [12766576.001]
  • [Cites] Histopathology. 2003 Jul;43(1):26-32 [12823709.001]
  • [Cites] Cancer Res. 2003 Jul 1;63(13):3695-700 [12839961.001]
  • [Cites] Fam Cancer. 2003;2(2):73-8 [14574155.001]
  • [Cites] Int J Gynecol Pathol. 2004 Jan;23(1):35-40 [14668548.001]
  • [Cites] Int J Gynecol Pathol. 2004 Jan;23(1):41-4 [14668549.001]
  • [Cites] Mol Reprod Dev. 2004 Feb;67(2):243-50 [14694441.001]
  • [Cites] Cancer Cell. 2004 Jan;5(1):19-24 [14749123.001]
  • [Cites] Breast J. 2004 Jan-Feb;10 Suppl 1:S5-9 [14984481.001]
  • [Cites] Gynecol Oncol. 2004 Mar;92(3):819-26 [14984947.001]
  • [Cites] Gynecol Oncol. 2005 May;97(2):476-82 [15863147.001]
  • [Cites] Clin Cancer Res. 2005 Sep 15;11(18):6422-30 [16166416.001]
  • [Cites] Gynecol Oncol. 2005 Oct;99(1):248-50 [16095676.001]
  • [Cites] Clin Cancer Res. 2005 Oct 15;11(20):7273-9 [16243797.001]
  • [Cites] Cancer Res. 2005 Nov 15;65(22):10602-12 [16288054.001]
  • [Cites] Int J Gynecol Cancer. 2005 Nov-Dec;15 Suppl 3:274-81 [16343244.001]
  • [Cites] Gynecol Oncol. 2006 Jan;100(1):58-64 [16137750.001]
  • [Cites] Am J Surg Pathol. 2006 Feb;30(2):230-6 [16434898.001]
  • [Cites] Mol Cell Endocrinol. 2006 Mar 9;247(1-2):4-21 [16297528.001]
  • [Cites] Science. 2006 May 26;312(5777):1168-71 [16728630.001]
  • [Cites] Am J Obstet Gynecol. 2006 Jun;194(6):1702-9 [16731090.001]
  • [Cites] Nature. 2006 Nov 30;444(7119):633-7 [17136093.001]
  • [Cites] Cancer Res. 2006 Dec 1;66(23):11125-30 [17145855.001]
  • [Cites] J Pathol. 2007 Jan;211(1):26-35 [17117391.001]
  • [Cites] Cancer Res. 2006 Dec 15;66(24):11565-70 [17178846.001]
  • [Cites] Curr Opin Obstet Gynecol. 2007 Feb;19(1):3-9 [17218844.001]
  • [Cites] Am J Surg Pathol. 2007 Feb;31(2):161-9 [17255760.001]
  • [Cites] Gynecol Oncol. 2007 Feb;104(2):331-7 [17064757.001]
  • [Cites] Recent Results Cancer Res. 2007;174:91-100 [17302189.001]
  • [Cites] Cancer Res. 2007 Apr 1;67(7):2990-3001 [17409405.001]
  • [Cites] Clin Med Res. 2007 Mar;5(1):35-44 [17456833.001]
  • [Cites] Br J Radiol. 2007 Sep;80 Spec No 1:S13-22 [17704321.001]
  • [Cites] J Clin Oncol. 2007 Sep 1;25(25):3985-90 [17761984.001]
  • [Cites] Int J Gynecol Pathol. 2008 Jan;27(1):1-9 [18156967.001]
  • [Cites] J Clin Oncol. 2008 Feb 20;26(6):995-1005 [18195328.001]
  • [Cites] Science. 2008 Mar 7;319(5868):1352-5 [18323444.001]
  • [Cites] Gynecol Oncol. 2008 May;109(2):168-73 [18342932.001]
  • [Cites] Histopathology. 2008 Aug;53(2):127-38 [18298580.001]
  • [Cites] J Clin Oncol. 2008 Sep 1;26(25):4160-5 [18757330.001]
  • [Cites] Gynecol Oncol. 2002 Oct;87(1):52-6 [12468342.001]
  • [Cites] J Clin Oncol. 2005 Jan 1;23(1):127-32 [15625367.001]
  • [Cites] J Cell Sci. 2004 Mar 15;117(Pt 8):1329-37 [14996907.001]
  • [Cites] Br J Cancer. 2004 Apr 19;90(8):1492-7 [15083174.001]
  • [Cites] Am J Pathol. 2004 May;164(5):1511-8 [15111296.001]
  • [Cites] J Mol Endocrinol. 2004 Jun;32(3):615-25 [15171704.001]
  • [Cites] Am J Surg Pathol. 2004 Aug;28(8):1112-4 [15252324.001]
  • [Cites] Reprod Biol Endocrinol. 2003 Oct 7;1:70 [14609432.001]
  • [Cites] Am J Pathol. 2004 Aug;165(2):397-414 [15277215.001]
  • [Cites] Hum Pathol. 2004 Aug;35(8):1014-21 [15297969.001]
  • [Cites] Am J Obstet Gynecol. 2004 Sep;191(3):718-32 [15467531.001]
  • [Cites] Lancet. 1971 Jul 17;2(7716):163 [4104488.001]
  • [Cites] Am J Pathol. 1977 Jun;87(3):686-720 [194486.001]
  • [Cites] Obstet Gynecol Surv. 1979 Apr;34(4):257-70 [471364.001]
  • [Cites] Diagn Gynecol Obstet. 1981 Spring;3(1):49-60 [7215124.001]
  • [Cites] Am J Obstet Gynecol. 1983 Sep 1;147(1):1-6 [6614075.001]
  • [Cites] J Natl Cancer Inst. 1983 Oct;71(4):711-6 [6578366.001]
  • [Cites] J Natl Cancer Inst. 1983 Oct;71(4):717-21 [6578367.001]
  • [Cites] J Membr Biol. 1985;88(2):149-63 [4093958.001]
  • [Cites] Environ Health Perspect. 1987 Aug;73:35-51 [3665870.001]
  • [Cites] Hum Reprod. 1989 Apr;4(3):229-35 [2715297.001]
  • [Cites] Hum Reprod. 1989 Jul;4(5):486-94 [2794010.001]
  • [Cites] Gynecol Oncol. 1989 Nov;35(2):236-9 [2807017.001]
  • [Cites] Hum Reprod. 1990 Jan;5(1):25-31 [2182659.001]
  • [Cites] Hum Reprod. 1992 Sep;7(8):1144-9 [1400940.001]
  • [Cites] Trends Genet. 1993 Apr;9(4):138-41 [8516849.001]
  • [Cites] Obstet Gynecol. 1993 Aug;82(2):181-6 [8336861.001]
  • [Cites] Cancer. 1994 Apr 1;73(7):1859-64 [8137211.001]
  • [Cites] Fertil Steril. 1994 Jun;61(6):1103-8 [8194625.001]
  • [Cites] N Engl J Med. 1994 Sep 22;331(12):771-6 [8065405.001]
  • [Cites] Biol Cell. 1994;82(2-3):103-7 [7606207.001]
  • [Cites] Biol Reprod. 1996 Feb;54(2):436-45 [8788197.001]
  • [Cites] Obstet Gynecol. 1996 Oct;88(4 Pt 1):554-9 [8841217.001]
  • [Cites] J Natl Cancer Inst. 1996 Dec 18;88(24):1810-20 [8961970.001]
  • [Cites] N Engl J Med. 1997 May 15;336(20):1401-8 [9145676.001]
  • (PMID = 18854563.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / K08 CA108748; United States / NCI NIH HHS / CA / P50 CA105009; United States / NCI NIH HHS / CA / R21 CA12468
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 119
  • [Other-IDs] NLM/ PMC2652087
  •  go-up   go-down


23. Zhang J, Li YL, Zhou CY, Hu YT, Chen HZ: Expression of octamer-4 in serous and mucinous ovarian carcinoma. J Clin Pathol; 2010 Oct;63(10):879-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of octamer-4 in serous and mucinous ovarian carcinoma.
  • AIMS: To assess the expression of Oct4 in epithelial ovarian tumours.
  • METHODS: Expression of Oct4 was evaluated by immunohistochemistry in 460 cases of various epithelial ovarian lesions as well as 35 cases of normal fallopian tube epithelium.
  • RESULTS: Oct4 expression was significantly increased from normal epithelium (both ovarian epithelium and fallopian tube epithelium) to benign and borderline cystadenoma to carcinoma in the serous lesion subgroup.
  • CONCLUSION: Results suggest that Oct4 expression may contribute to the initiation, promotion and progression of serous ovarian carcinoma; it might be a useful biomarker for the diagnosis and outcome prediction of serous ovarian carcinoma.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / metabolism. Cystadenoma / metabolism. Octamer Transcription Factor-3 / metabolism. Ovarian Neoplasms / metabolism
  • [MeSH-minor] Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Disease Progression. Epithelium / metabolism. Fallopian Tubes / metabolism. Female. Humans. Neoplasm Proteins / metabolism. Neoplasm Staging. Ovary / metabolism

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20876318.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / Octamer Transcription Factor-3; 0 / POU5F1 protein, human
  •  go-up   go-down


24. Shih IeM, Chen L, Wang CC, Gu J, Davidson B, Cope L, Kurman RJ, Xuan J, Wang TL: Distinct DNA methylation profiles in ovarian serous neoplasms and their implications in ovarian carcinogenesis. Am J Obstet Gynecol; 2010 Dec;203(6):584.e1-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distinct DNA methylation profiles in ovarian serous neoplasms and their implications in ovarian carcinogenesis.
  • OBJECTIVE: The purpose of this study was to analyze DNA methylation profiles among different types of ovarian serous neoplasm, which is a task that has not been performed.
  • STUDY DESIGN: The Illumina beads array (Illumina Inc, San Diego, CA) was used to profile DNA methylation in enriched tumor cells that had been isolated from 75 benign and malignant serous tumor tissues and 6 tumor-associated stromal cell cultures.
  • RESULTS: We found significantly fewer hypermethylated genes in high-grade serous carcinomas than in low-grade serous carcinoma and borderline tumors, which in turn had fewer hypermethylated genes than serous cystadenoma.
  • Unsupervised analysis identified that serous cystadenoma, serous borderline tumor, and low-grade serous carcinomas tightly clustered together and were clearly different from high-grade serous carcinomas.
  • CONCLUSION: The findings support the view that low-grade and high-grade serous carcinomas are distinctly different with low-grade, but not high-grade, serous carcinomas that are related to serous borderline tumor and cystadenoma.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Mosby, Inc. All rights reserved.
  • [Cites] Am J Pathol. 2002 Apr;160(4):1223-8 [11943707.001]
  • [Cites] Clin Cancer Res. 2010 Apr 1;16(7):1997-2008 [20233889.001]
  • [Cites] J Natl Cancer Inst. 2003 Mar 19;95(6):484-6 [12644542.001]
  • [Cites] J Biochem. 2003 Mar;133(3):303-8 [12761165.001]
  • [Cites] Nat Genet. 2003 Jul;34(3):337-43 [12819783.001]
  • [Cites] N Engl J Med. 2003 Nov 20;349(21):2042-54 [14627790.001]
  • [Cites] Ann Oncol. 2004 Feb;15(2):252-6 [14760118.001]
  • [Cites] Am J Pathol. 2004 May;164(5):1511-8 [15111296.001]
  • [Cites] Cancer Res. 2004 Sep 15;64(18):6476-81 [15374957.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):6915-8 [15466181.001]
  • [Cites] Curr Opin Oncol. 2005 Jan;17(1):33-8 [15608510.001]
  • [Cites] Cancer Res. 2005 Jun 1;65(11):4963-8 [15930319.001]
  • [Cites] Oncogene. 2005 Jun 2;24(24):3875-85 [15735666.001]
  • [Cites] Cancer. 2005 Nov 1;104(9):1924-30 [16134181.001]
  • [Cites] Clin Cancer Res. 2005 Oct 15;11(20):7273-9 [16243797.001]
  • [Cites] Nat Rev Cancer. 2006 Feb;6(2):107-16 [16491070.001]
  • [Cites] Virchows Arch. 2006 Mar;448(3):331-6 [16315018.001]
  • [Cites] Cancer. 2006 Jul 15;107(2):299-308 [16773633.001]
  • [Cites] Am J Surg Pathol. 2007 Jul;31(7):1007-12 [17592266.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5116-21 [11309499.001]
  • [Cites] J Urol. 2008 Feb;179(2):743-7 [18082200.001]
  • [Cites] Int J Gynecol Pathol. 2008 Apr;27(2):151-60 [18317228.001]
  • [Cites] Gynecol Oncol. 2008 Apr;109(1):129-39 [18234305.001]
  • [Cites] Int J Cancer. 2008 Aug 1;123(3):725-9 [18478570.001]
  • [Cites] Gynecol Oncol. 2008 Nov;111(2):320-9 [18757082.001]
  • [Cites] Am J Obstet Gynecol. 2009 Feb;200(2):177.e1-9 [19110234.001]
  • [Cites] Annu Rev Pathol. 2009;4:287-313 [18842102.001]
  • [Cites] Cancer Res. 2009 May 1;69(9):4036-42 [19383911.001]
  • [Cites] Cancer Res. 2009 Nov 1;69(21):8482-90 [19826047.001]
  • [Cites] J Clin Oncol. 2009 Dec 10;27(35):5874-80 [19901110.001]
  • [Cites] PLoS One. 2010;5(2):e9359 [20179752.001]
  • [Cites] Lab Invest. 2010 Mar;90(3):414-25 [20065949.001]
  • [Cites] Clin Cancer Res. 2002 Jul;8(7):2246-52 [12114427.001]
  • (PMID = 20965493.001).
  • [ISSN] 1097-6868
  • [Journal-full-title] American journal of obstetrics and gynecology
  • [ISO-abbreviation] Am. J. Obstet. Gynecol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA103937; United States / NCI NIH HHS / CA / CA103937-07; United States / NCI NIH HHS / CA / R01 CA129080-04; United States / NCI NIH HHS / CA / CA129080; United States / NCI NIH HHS / CA / R01 CA129080; United States / NCI NIH HHS / CA / CA129080-04; United States / NCI NIH HHS / CA / R01 CA103937-07; United States / NCI NIH HHS / CA / R01 CA103937
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS230506; NLM/ PMC2993872
  •  go-up   go-down


25. Wanapirak C, Srisupundit K, Tongsong T: Sonographic morphology scores (SMS) for differentiation between benign and malignant adnexal masses. Asian Pac J Cancer Prev; 2006 Jul-Sep;7(3):407-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sonographic morphology scores (SMS) for differentiation between benign and malignant adnexal masses.
  • OBJECTIVE: To determine the sensitivity and specificity of a scoring system for distinguishing between benign and malignant adnexal masses and to detect threshold scores for prediction of malignant ovarian tumors.
  • SUBJECTS: A total 158 patients scheduled for elective surgery due to ovarian tumors at Maharaj Nakorn Chiang Mai Hospital between June 16, 2002 and August 8, 2004 were recruited into the study.
  • CONCLUSION: Sonographic morphology scores are useful in distinguishing adnexal malignancies from benign lesions in some selected cases.
  • [MeSH-major] Adnexal Diseases / diagnostic imaging. Ovarian Neoplasms / diagnostic imaging. Ultrasonography, Doppler
  • [MeSH-minor] Adenocarcinoma, Clear Cell / ultrastructure. Adenocarcinoma, Mucinous / ultrastructure. Adolescent. Adult. Aged. Carcinoma, Endometrioid / ultrastructure. Cross-Sectional Studies. Cystadenoma, Serous / ultrastructure. Diagnosis, Differential. Female. Humans. Incidence. Middle Aged. Neoplasm Staging. Predictive Value of Tests. ROC Curve. Risk Factors. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17059332.001).
  • [ISSN] 1513-7368
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


26. Jeurnink SM, Vleggaar FP, Siersema PD: Overview of the clinical problem: facts and current issues of mucinous cystic neoplasms of the pancreas. Dig Liver Dis; 2008 Nov;40(11):837-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mucinous cystic neoplasms are large septated cysts without connection to the ductal system, characterised by the presence of thick-walled ovarian-type stroma and mucin.
  • They mainly occur in women in their 50s and are generally benign.
  • A number of management issues regarding these neoplasms are still under debate, for example which imaging technique to use, differentiation between malignant or benign lesions and the preferred treatment modality for each pancreatic cystic neoplasm.
  • [MeSH-major] Carcinoembryonic Antigen / analysis. Cystadenocarcinoma / pathology. Cystadenoma, Mucinous / pathology. Cystadenoma, Serous / pathology. Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18499541.001).
  • [ISSN] 1878-3562
  • [Journal-full-title] Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  • [ISO-abbreviation] Dig Liver Dis
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen
  • [Number-of-references] 46
  •  go-up   go-down


27. Hayashi M, Shibazaki M, Sohma R, Inaba N: Effects of histologic type on levels of macrophage colony-stimulating factor in liquid contents of benign ovarian tumors. Am J Med Sci; 2006 Oct;332(4):181-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of histologic type on levels of macrophage colony-stimulating factor in liquid contents of benign ovarian tumors.
  • BACKGROUND: Normal ovarian tissue is rich in cytokines.
  • Cytokines are important in the physiology of ovarian function.
  • Most of the same cytokines that are found in normal ovarian tissue are also found in association with benign and malignant tumors in contrast to their functions in normal tissues.
  • Thus, we measured macrophage colony-stimulating factor (M-CSF) levels in the liquid contents of benign ovarian tumors--serous cystadenoma, mucinous cystadenoma, and mature cystic teratoma--and investigated whether M-CSF levels were associated with the histologic type of the ovarian tumors.
  • METHODS: We enrolled 65 patients, 52 with benign ovarian tumor and 13 in the early postmenopausal period with symptoms of a menopausal disorder.
  • Among the 52 patients with benign ovarian tumor, 16 had serous cystadenoma, 21 had mucinous cystadenoma, and 15 had mature cystic teratoma.
  • Immediately after surgery, the liquid content was drawn from the ovarian tumor, then centrifuged, and the separated supernatant was stored at -30 degrees C.
  • RESULTS: The level of M-CSF was 12,513 U/mL (median) (range, 0-169,000 U/mL) in serous cystadenoma, 915 U/mL (0-82,500 U/mL) in mucinous cystadenoma, and 149 U/mL (0-6,230 U/mL) in mature cystic teratoma.
  • The M-CSF levels increased significantly from mature cystic teratoma to mucinous cystadenoma to serous cystadenoma.
  • The serum M-CSF levels were 308 to 499 U/mL in patients with benign ovarian tumor.
  • CONCLUSIONS: Elevation of levels of M-CSF varies according to histologic type in benign ovarian tumors.
  • This implies that the antitumor activities of M-CSF for serous cystadenoma, mucinous cystadenoma, and mature cystic teratoma differ by histologic type.
  • [MeSH-major] Extracellular Fluid / metabolism. Macrophage Colony-Stimulating Factor / metabolism. Neoplasm Proteins / metabolism. Neoplasms / metabolism. Neoplasms / pathology. Ovarian Neoplasms / metabolism. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17031243.001).
  • [ISSN] 0002-9629
  • [Journal-full-title] The American journal of the medical sciences
  • [ISO-abbreviation] Am. J. Med. Sci.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 81627-83-0 / Macrophage Colony-Stimulating Factor
  •  go-up   go-down


28. Karaman A, Azili MN, Boduroğlu EC, Karaman I, Erdoğan D, Cavuşoğlu YH, Aslan MK, Cakmak O: A huge ovarian mucinous cystadenoma in a 14-year-old premenarchal girl: review on ovarian mucinous tumor in premenarchal girls. J Pediatr Adolesc Gynecol; 2008 Feb;21(1):41-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A huge ovarian mucinous cystadenoma in a 14-year-old premenarchal girl: review on ovarian mucinous tumor in premenarchal girls.
  • Superficial epithelial ovarian tumors are unusual in adolescent girls (when compared with adult women) and extremely rare before menarche.
  • Mucinous cystadenoma (MCA) in children that is a rare form of epithelial tumor is a benign cystic ovarian neoplasm.
  • To our knowledge, there are only eight cases of mucinous cystadenoma, three of borderline mucinous cystadenoma, and three of mucinous cystadenocarcinoma reported in the English-language literature.
  • We present a 14-year-old premenarchal girl with a giant ovarian mucinous cystadenoma.
  • This review is supported by the finding that epithelial ovarian neoplasms are extremely rare prior to puberty and that only 14 mucinous tumors have been reported prior to menarche.
  • [MeSH-major] Cystadenoma, Mucinous / pathology. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18312801.001).
  • [ISSN] 1083-3188
  • [Journal-full-title] Journal of pediatric and adolescent gynecology
  • [ISO-abbreviation] J Pediatr Adolesc Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 12
  •  go-up   go-down


29. Moszyński R, Szpurek D, Pawlak M, Englert-Golon M, Sajdak S: [The influence of ovarian tumour histopathological diagnosis on prognostic values of the sonomorphological index]. Ginekol Pol; 2006 Jul;77(7):516-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The influence of ovarian tumour histopathological diagnosis on prognostic values of the sonomorphological index].
  • OBJECTIVES: The purpose of the study was to evaluate the helpfulness of sonomorphological index in preoperative diagnosis of ovarian tumours.
  • During the study, histopathological types of ovarian tumours with the lowest prognostic values were appointed.
  • Among benign tumours the lowest helpfulness in preoperative diagnosis of ovarian tumours the sonomorphological index demonstrated in following histopathological types: mucinouse cystadenoma and adult teratoma.
  • Particular histopathological diagnosis is the tubo-ovarian abscess--all analyzed cases had a false positive result in the test.
  • CONCLUSIONS: In all histopathological types of malignant and benign tumours mentioned above, the use of the sonomorphological index require caution.
  • [MeSH-major] Ovarian Neoplasms / diagnostic imaging. Ovarian Neoplasms / pathology. Women's Health
  • [MeSH-minor] Adolescent. Adult. Aged. Diagnosis, Differential. Female. Humans. Imaging, Three-Dimensional / methods. Middle Aged. Ovarian Cysts / diagnostic imaging. Ovarian Cysts / pathology. Predictive Value of Tests. Preoperative Care / methods. Retrospective Studies. Sensitivity and Specificity. Ultrasonography

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Women's Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17076201.001).
  • [ISSN] 0017-0011
  • [Journal-full-title] Ginekologia polska
  • [ISO-abbreviation] Ginekol. Pol.
  • [Language] pol
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


30. Wang HX, Chen G, Li GL, Jiang YJ: [Expression and significance of Survivin and Smac in ovarian mucinous tumors]. Zhonghua Bing Li Xue Za Zhi; 2010 Jun;39(6):387-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression and significance of Survivin and Smac in ovarian mucinous tumors].
  • OBJECTIVE: To investigate the expressions and significances of Survivin and Smac in ovarian mucinous tumors.
  • METHODS: A total of 55 paraffin-embedded specimens of primary ovarian mucinous tumors were collected.
  • (1) The cytoplasmic expression rates of survivin in benign, borderline and malignant ovarian mucinous tumors were 2/20, 12/15 and 20/20 respectively, which presents an improving trend.There were significant differences of survivin expression between benign vs. borderline lesions (P < 0.01), and benign vs. malignant tumors (P < 0.01).
  • The nuclear expression rates of survivin in benign, borderline and malignant ovarian mucinous tumors were 1/20, 6/15 and 5/20, respectively, which presents a.declining trend.There was significant difference of survivin expression between benign vs. borderline tumors (P < 0.05).
  • CONCLUSIONS: With the malignant development of ovarian mucinous tumors, the expressions of Survivin are up-regulated, and the expressions of Smac are down-regulated.
  • [MeSH-major] Cystadenocarcinoma, Mucinous / metabolism. Cystadenoma, Mucinous / metabolism. Intracellular Signaling Peptides and Proteins / metabolism. Microtubule-Associated Proteins / metabolism. Mitochondrial Proteins / metabolism. Ovarian Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21055155.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / DIABLO protein, human; 0 / Inhibitor of Apoptosis Proteins; 0 / Intracellular Signaling Peptides and Proteins; 0 / Microtubule-Associated Proteins; 0 / Mitochondrial Proteins
  •  go-up   go-down


31. Kelly PJ, Archbold P, Price JH, Cardwell C, McCluggage WG: Serum CA19.9 levels are commonly elevated in primary ovarian mucinous tumours but cannot be used to predict the histological subtype. J Clin Pathol; 2010 Feb;63(2):169-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum CA19.9 levels are commonly elevated in primary ovarian mucinous tumours but cannot be used to predict the histological subtype.
  • Limited studies have shown that this tumour marker may also be elevated in primary ovarian mucinous neoplasms, but no study has assessed whether serum CA19.9 levels can be used to predict if a primary ovarian mucinous tumour is benign, borderline or malignant.
  • The aim of this study was to correlate the serum CA19.9 level with the histological features in a large series of primary ovarian mucinous neoplasms.
  • METHODS: 144 cases of primary ovarian mucinous neoplasm (79 benign, 45 borderline and 20 malignant) were identified in which a preoperative serum CA19.9 level had been performed.
  • There was no relationship between the serum CA19.9 level and whether the tumours were benign, borderline or malignant (Kruskal-Wallis test p value=0.32).
  • CONCLUSION: Preoperative CA19.9 levels cannot be used to predict whether a suspected ovarian mucinous tumour is benign, borderline or malignant.
  • Markedly elevated serum levels (>1000 U/ml) may be found in benign mucinous neoplasms as well as in borderline and malignant tumours.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. CA-19-9 Antigen / blood. Cystadenoma, Mucinous / diagnosis. Ovarian Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20154039.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CA-19-9 Antigen
  •  go-up   go-down


32. Marana R, Muzii L, Ferrari S, Catalano GF, Zannoni G, Marana E: Management of adnexal cystic masses with unexpected intracystic vegetations detected during laparoscopy. J Minim Invasive Gynecol; 2005 Nov-Dec;12(6):502-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Frozen section diagnosis was benign in 32 patients and borderline in 3 patients.
  • Final pathology diagnosis was borderline ovarian tumor in five of the 35 patients (14.3%), and benign in 30 patients (85.7%).
  • [MeSH-major] Adnexal Diseases / diagnosis. Cystadenoma / diagnosis. Ovarian Cysts / surgery

  • MedlinePlus Health Information. consumer health - Ovarian Cysts.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16337577.001).
  • [ISSN] 1553-4650
  • [Journal-full-title] Journal of minimally invasive gynecology
  • [ISO-abbreviation] J Minim Invasive Gynecol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Reed J, Hakam A, Nicosia SV, Coppola D: Significance of Fas receptor protein expression in epithelial ovarian cancer. Hum Pathol; 2005 Sep;36(9):971-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Significance of Fas receptor protein expression in epithelial ovarian cancer.
  • It has been postulated that this receptor may be involved in the clearance of benign ovarian epithelial inclusion cysts (IC).
  • In this study, we test the hypothesis that the expression of FasR changes among IC, cystadenoma (AD), tumors of low malignant potential (LMP), and invasive cancer (cystadenocarcinoma, CA).
  • The decreased expression of FasR in malignant ovarian epithelial neoplasms as compared with benign ovarian epithelial lesions suggests that a decreased sensitivity to Fas-mediated apoptosis may be involved in ovarian epithelial carcinogenesis.
  • [MeSH-major] Antigens, CD95 / metabolism. Cystadenocarcinoma, Papillary / metabolism. Cystadenoma, Serous / metabolism. Membrane Glycoproteins / metabolism. Ovarian Neoplasms / metabolism


34. Mahdavi A, Kumtepe Y, Nezhat F: Laparoscopic management of benign serous neoplasia arising from persistent ovarian remnant. J Minim Invasive Gynecol; 2007 Sep-Oct;14(5):654-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic management of benign serous neoplasia arising from persistent ovarian remnant.
  • Serous cystadenoma arising from ovarian remnant has not been reported in the literature.
  • We report 3 cases with ovarian remnant syndrome that were treated with laparoscopic excision and were proven to be benign serous neoplasia with ovarian origin on final pathologic examination.
  • We review the current evidence for malignant transformation potential of ovarian serous cystadenoma and discuss laparoscopic techniques for management of ovarian remnant syndrome.
  • [MeSH-major] Cystadenocarcinoma, Serous / surgery. Laparoscopy / methods. Ovarian Neoplasms / surgery. Ovariectomy / adverse effects
  • [MeSH-minor] Adult. Female. Humans. Middle Aged. Ovarian Diseases / complications. Pelvic Pain / etiology. Pelvic Pain / surgery. Syndrome

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17848331.001).
  • [ISSN] 1553-4650
  • [Journal-full-title] Journal of minimally invasive gynecology
  • [ISO-abbreviation] J Minim Invasive Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Koskas M, Martin B, Madelenat P: [Cystadenofibroma of the ovary: report of two cases]. J Gynecol Obstet Biol Reprod (Paris); 2009 Sep;38(5):431-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cystadenofibroma of the ovary: report of two cases].
  • Cystadenofibroma of the ovary is a relatively rare benign tumor.
  • We present two cases of cystadenofibromas of the ovary.
  • [MeSH-major] Adenofibroma / surgery. Cystadenoma / surgery. Ovarian Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19559542.001).
  • [ISSN] 0368-2315
  • [Journal-full-title] Journal de gynécologie, obstétrique et biologie de la reproduction
  • [ISO-abbreviation] J Gynecol Obstet Biol Reprod (Paris)
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


36. Sutnar A, Skalický T, Treska V, Hess O, Mírka H, Michal M, Novák P, Liska V: [Liver cystadenoma with ovarian stroma--a case review]. Rozhl Chir; 2008 May;87(5):259-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Liver cystadenoma with ovarian stroma--a case review].
  • [Transliterated title] Cystadenom jater s ovariálním stromatem--kazuistika.
  • Cystadenoma with ovarian type of stroma is a rare liver tumor.
  • [MeSH-major] Cystadenoma / pathology. Liver Neoplasms / pathology. Stromal Cells / pathology
  • [MeSH-minor] Female. Humans. Middle Aged. Ovary

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18595544.001).
  • [ISSN] 0035-9351
  • [Journal-full-title] Rozhledy v chirurgii : měsíčník Československé chirurgické společnosti
  • [ISO-abbreviation] Rozhl Chir
  • [Language] cze
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Czech Republic
  •  go-up   go-down


37. Coronado Martín PJ, Fasero Laiz M, García Santos J, Ramírez Mena M, Vidart Aragón JA: [Overexpression and prognostic value of p53 and HER2/neu proteins in benign ovarian tissue and in ovarian cancer]. Med Clin (Barc); 2007 Jan 13;128(1):1-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Overexpression and prognostic value of p53 and HER2/neu proteins in benign ovarian tissue and in ovarian cancer].
  • BACKGROUND AND OBJECTIVE: To investigate the prognostic value of p53 and HER2/neu overexpression in epithelial ovarian cancer (EOC).
  • PATIENTS AND METHOD: p53 and HER2/neu immunostaining were performed in 198 tissue samples, 124 EOC, 44 benign ovarian tumors and 30 normal ovaries.
  • RESULTS: Neither p53 nor HER2/neu overexpression was seen in the benign ovarian tumors.
  • HER2/neu immunostaining was observed in one normal ovary.
  • [MeSH-major] Cystadenoma, Mucinous / genetics. Cystadenoma, Serous / genetics. Ovarian Neoplasms / genetics. Receptor, ErbB-2 / genetics. Teratoma / genetics. Tumor Suppressor Protein p53 / genetics
  • [MeSH-minor] Aged. Biomarkers, Tumor. Confidence Intervals. Endometriosis / genetics. Endometriosis / pathology. Endometriosis / surgery. Female. Follow-Up Studies. Genes, p53. Humans. Immunohistochemistry. Middle Aged. Multivariate Analysis. Neoplasm Recurrence, Local. Neoplasm Staging. Ovarian Diseases / genetics. Ovarian Diseases / pathology. Ovarian Diseases / surgery. Prognosis. Proportional Hazards Models. Risk. Survival Analysis. Time Factors


38. Ahmed Z, Aftab K, Kayani N: Ovarian primary neuroendocrine carcinoma of non-small cell type: report of an extremely rare neoplasm. J Pak Med Assoc; 2005 Feb;55(2):82-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian primary neuroendocrine carcinoma of non-small cell type: report of an extremely rare neoplasm.
  • Paraffin block sections of a uterus and ovarian mass from a 31 year old female were sent for second opinion to the Pathology Laboratory of Aga Khan University.
  • Histologic examination and immunohistochemical features gave a diagnosis of primary neuroendocrine carcinoma of non-small cell type admixed with benign mucinous cystadenoma.
  • [MeSH-major] Carcinoma, Neuroendocrine / pathology. Cystadenoma, Mucinous / pathology. Ovarian Neoplasms / pathology

  • Genetic Alliance. consumer health - Ovarian small cell carcinoma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15813637.001).
  • [ISSN] 0030-9982
  • [Journal-full-title] JPMA. The Journal of the Pakistan Medical Association
  • [ISO-abbreviation] J Pak Med Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Pakistan
  •  go-up   go-down


39. Ueda M, Toji E, Noda S: Germ line and somatic mutations of BRAF V599E in ovarian carcinoma. Int J Gynecol Cancer; 2007 Jul-Aug;17(4):794-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Germ line and somatic mutations of BRAF V599E in ovarian carcinoma.
  • It has been shown that ovarian low-grade serous carcinoma evolves out of a stepwise progression from benign serous cystadenoma to serous borderline tumor (SBT) to micropapillary serous carcinoma (MPSC), and that BRAF activation is a very early somatic event in the tumorigenesis.
  • We postulated that BRAF could be a SBT susceptibility gene, and investigated both germ line and somatic mutations of BRAF V599E in 104 ovarian cancer patients.
  • We also found no BRAF V599E mutation in 101 normal healthy women and 10 well-established ovarian cancer cell lines.
  • [MeSH-major] Cystadenoma, Serous / genetics. Mutation. Ovarian Neoplasms / genetics. Proto-Oncogene Proteins B-raf / genetics

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17309670.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf
  •  go-up   go-down


40. Poli Neto OB, Candido Dos Reis FJ, Zambelli Ramalho LN, Nogueira AA, de Andrade JM: p63 expression in epithelial ovarian tumors. Int J Gynecol Cancer; 2006 Jan-Feb;16(1):152-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p63 expression in epithelial ovarian tumors.
  • Ovarian cancer is a highly lethal disease and its underlying biology is poorly understood.
  • This study presents the immunoexpression of the p63 in benign and malignant epithelial ovarian tumors.
  • We evaluated the p63 immunoexpression in 91 ovarian benign cystadenomas (29 mucinous and 62 serous) and in 29 ovarian malignant tumors (3 mucinous borderline, 3 serous borderline, 17 serous carcinomas, 2 endometrioid, 2 undifferentiated, 1 mucinous, and 1 clear-cell carcinoma) using a monoclonal antibody clone 4A4 (1:200), which recognizes all p63 variants.
  • We observed 85.7% of positivity in benign tumors, 50% in borderline tumors, and 8.7% in invasive ovarian cancer (P < .0001).
  • The benign serous cystadenomas were positive in 91.9% of cases and benign mucinous cystadenomas in 72.4% (P= .02).
  • These data suggests an important role of p63 in the control of ovarian epithelium behavior.
  • The p63 may be involved in the development of benign and malignant epithelial ovarian tumors.
  • [MeSH-major] Carcinoma / genetics. Carcinoma / pathology. Cystadenoma / pathology. Ovarian Neoplasms / genetics. Ovarian Neoplasms / pathology. Phosphoproteins / metabolism. Trans-Activators / metabolism

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16445626.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Phosphoproteins; 0 / TP63 protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


41. Eltabbakh GH, Charboneau AM, Eltabbakh NG: Laparoscopic surgery for large benign ovarian cysts. Gynecol Oncol; 2008 Jan;108(1):72-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic surgery for large benign ovarian cysts.
  • OBJECTIVE: To assess the feasibility and surgical outcome of laparoscopic surgery among women with large benign ovarian cysts.
  • METHODS: We conducted a prospective study applying laparoscopic surgery among women with ovarian cysts whose maximum diameter was > or = 10 cm and radiologic and laboratory features suggestive of benign disease.
  • The surgical procedures performed were: unilateral salpingo-oophorectomy (SO) (n=16), bilateral SO (n=4), ovarian cystectomy (n=2) and laparoscopically assisted vaginal hysterectomy and bilateral SO (n=9).
  • Pathologic findings included serous cystadenoma (n=11), mucinous cystadenoma (n=6), dermoid (n=6), endometriosis (n=5), benign epithelial-lined cyst (n=3) and borderline ovarian tumors (n=2).
  • CONCLUSION: Laparoscopy is feasible and safe for women with large ovarian cysts with benign features and results in a short hospital stay.
  • [MeSH-major] Ovarian Cysts / surgery

  • MedlinePlus Health Information. consumer health - Ovarian Cysts.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17949797.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


42. Nwobodo EI: Giant mucinous cystadenoma: case report. Niger J Clin Pract; 2010 Jun;13(2):228-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant mucinous cystadenoma: case report.
  • Mucinous tumours are the second most common type of epithelial ovarian tumours.
  • Majority of these tumours are benign.
  • However, some of these benign lesion can grow to enormous size, thus stimulating malignant neoplasia.
  • Abdomino-pelvic ultrasound scan revealed a large left ovarian cyst.
  • A huge mucinous cystadenoma weighing 33.6 kg was removed.
  • [MeSH-major] Cystadenoma, Mucinous / pathology. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20499763.001).
  • [ISSN] 1119-3077
  • [Journal-full-title] Nigerian journal of clinical practice
  • [ISO-abbreviation] Niger J Clin Pract
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Nigeria
  •  go-up   go-down


43. Huang Y, Hua K, Zhou X, Jin H, Chen X, Lu X, Yu Y, Zha X, Feng Y: Activation of the PI3K/AKT pathway mediates FSH-stimulated VEGF expression in ovarian serous cystadenocarcinoma. Cell Res; 2008 Jul;18(7):780-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Activation of the PI3K/AKT pathway mediates FSH-stimulated VEGF expression in ovarian serous cystadenocarcinoma.
  • There is evidence to suggest that follicle-stimulating hormone (FSH) can facilitate the neovascularization of ovarian cancers by increasing vascular endothelial growth factor (VEGF) expression in cancer cells, although the underlying molecular mechanism of this process is not well known.
  • Therefore, we investigated the effect of FSH on VEGF expression in the ovarian cancer cell lines SKOV-3 and ES-2.
  • We further showed that ovarian serous cystadenocarcinoma samples had much higher incidence of positive AKT and phosphorylated AKT (pAKT) protein staining than did benign ovarian cystadenoma samples (p < 0.01).
  • The 5-year survival rate was only about 15% in patients with ovarian serous cystadenocarcinoma who had AKT and pAKT expression, whereas it was about 80% in those who did not have AKT or pAKT expression.
  • Understanding the role of the PI3K/AKT pathway in FSH-stimulated expression of survivin and VEGF will be beneficial for evaluating the prognosis for patients with ovarian serous cystadenocarcinoma and for pursuing effective treatment against this disease.
  • [MeSH-major] Cystadenocarcinoma, Serous / metabolism. Microtubule-Associated Proteins / metabolism. Neoplasm Proteins / metabolism. Ovarian Neoplasms / metabolism. Proto-Oncogene Proteins c-akt / metabolism. Signal Transduction. Vascular Endothelial Growth Factor A / genetics

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. MENOTROPINS .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18574502.001).
  • [ISSN] 1748-7838
  • [Journal-full-title] Cell research
  • [ISO-abbreviation] Cell Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / HIF1A protein, human; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; 0 / Vascular Endothelial Growth Factor A; 9002-68-0 / Follicle Stimulating Hormone; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt
  •  go-up   go-down


44. Uschuplich V, Hilsenbeck JR, Velasco CR: Paratesticular mucinous cystadenoma arising from an oviduct-like müllerian remnant: a case report and review of the literature. Arch Pathol Lab Med; 2006 Nov;130(11):1715-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paratesticular mucinous cystadenoma arising from an oviduct-like müllerian remnant: a case report and review of the literature.
  • A mucinous cystadenoma of the paratestis arising from an unequivocal oviduct-like structure in an 18-year-old man is reported.
  • Mucinous cystadenomas of the testis and paratestis are extremely rare benign tumors of controversial origin.
  • A few case reports and reviews of testicular and paratesticular mucinous neoplasms resembling ovarian tumors have suggested the possibility of a müllerian origin of these tumors.
  • [MeSH-major] Cystadenoma, Mucinous / etiology. Cystadenoma, Mucinous / pathology. Mullerian Ducts / pathology. Testicular Neoplasms / etiology. Testicular Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17076537.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 10
  •  go-up   go-down


45. Shao SL, Cai Y, Wang QH, Yan LJ, Zhao XY, Wang LX: [Expression of GLUT-1, p63 and DNA-Pkcs in serous ovarian tumors and their significance]. Zhonghua Zhong Liu Za Zhi; 2007 Sep;29(9):697-700
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of GLUT-1, p63 and DNA-Pkcs in serous ovarian tumors and their significance].
  • OBJECTIVE: To investigate the expression of GLUT1, p63 and DNA-Pkcs in serous ovarian tumors and their significance.
  • METHODS: GTUL1, p63 and DNA-Pkcs expression at protein level was detected by immunohistochemistry in patients with serous ovarian tumors.
  • RESULTS: Cells in the normal ovarian tissues were not stained with GTUL1 and p63 antiserum, but DNA-Pkcs was positively stained.
  • The intensity of GTUT1 and p63 expression was stronger in malignant ovarian serous tumors compared with other subtypes (P < 0.01).
  • There were significant differences of DNA-PKcs among normal ovaries (100.0%), benign (95.0%), borderline (90.0%) and malignant (60.0%) serious ovarian neoplasms (P < 0.01).
  • CONCLUSION: The results suggest that the abnormal expression of GTUT1, p63 and DNA-Pkcs may perhaps participate in serous ovarian tumor occurrence and development and may be considered as a marker reflecting tumor malignant behavior.
  • [MeSH-major] Cystadenocarcinoma, Serous / metabolism. DNA-Activated Protein Kinase / metabolism. Glucose Transporter Type 1 / metabolism. Nuclear Proteins / metabolism. Ovarian Neoplasms / metabolism. Trans-Activators / metabolism. Tumor Suppressor Proteins / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Cystadenoma, Serous / metabolism. Cystadenoma, Serous / pathology. Epithelium / metabolism. Female. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Ovary / cytology. Transcription Factors. Young Adult

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18246802.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Glucose Transporter Type 1; 0 / Nuclear Proteins; 0 / SLC2A1 protein, human; 0 / TP63 protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins; EC 2.7.11.1 / DNA-Activated Protein Kinase; EC 2.7.11.1 / PRKDC protein, human
  •  go-up   go-down


46. Mikhaleva LM, Moroz EA, Barkhina TG, Cherniaev AL, Samsonova MV, Solomatina AA: [Morphofunctional characteristics of microvessels in serous tumors of the ovaries]. Arkh Patol; 2005 Nov-Dec;67(6):28-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • High vascularization is noted in serous papillary ovarian tumors of a low malignancy grade, particularly in malignant serous ovarian tumors with low vascularization in benign neoplasms.
  • [MeSH-major] Cystadenocarcinoma, Serous / pathology. Cystadenoma, Serous / pathology. Neovascularization, Pathologic / pathology. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16405018.001).
  • [ISSN] 0004-1955
  • [Journal-full-title] Arkhiv patologii
  • [ISO-abbreviation] Arkh. Patol.
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


47. Takeuchi K, Kitazawa S, Deguchi M, Maruo T: Adenofibromasarcoma originating from a mural nodule of ovarian serous cystadenoma. Eur J Gynaecol Oncol; 2005;26(5):511-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenofibromasarcoma originating from a mural nodule of ovarian serous cystadenoma.
  • A 83-year-old woman received bilateral salpingo-oophorectomy and hysterectomy due to a provisional diagnosis of ovarian cystic tumor.
  • The tumor had a unilocular cystic cavity demonstrating serous cystadenoma and a solid mural nodule representing a biphasic pattern with mesenchymal and glandular components.
  • The glandular elements were composed of benign serous cells, whereas the mesenchymal components consisted of an admixture of fibromatous stromal cells without atypia and sarcomatous overgrowth.
  • To the authors' knowledge, this is the first reported case of adenofibrosarcoma originating from a mural nodule of ovarian serous cystadenoma.
  • [MeSH-major] Adenosarcoma / diagnosis. Cystadenoma, Serous / diagnosis. Neoplasms, Multiple Primary / diagnosis. Ovarian Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16285568.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


48. Chudecka-Głaz A, Rzepka-Górska I: Concentrations of follicle stimulating hormone are increased in ovarian tumor fluid: implications for the management of ovarian cancer. Eur J Gynaecol Oncol; 2008;29(1):37-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concentrations of follicle stimulating hormone are increased in ovarian tumor fluid: implications for the management of ovarian cancer.
  • PURPOSE OF INVESTIGATION: Significant progress has been made in recent years in the understanding of the mechanisms postulated by the gonadotropin theory of ovarian carcinogenesis.
  • They were divided into five groups: I (n = 44)--ovarian cancer patients, II (n = 16)--borderline tumors, III (n = 40)--benign epithelial cystadenomas, IV (n = 137)--non-neoplastic lesions and V (n = 22)--admitted for "second-look" laparoscopy.
  • RESULTS: There were any significant differences between FSH concentrations in serum and tumor fluid in patients with ovarian cancer (36.46 vs 28.11 mIU/ml) and borderline epithelial tumors (31.5 vs 22.7 mIU/ml).
  • For benign cystadenomas the respective concentrations were 28.96 mIU/ml in serum and 6.93 mIU/ml in tumor fluid in these groups p < 0.0000001.
  • Local reduction of FSH levels through administration of GnRH analogs may in some clinical situations produce clear therapeutic benefits for the management of ovarian malignancies.
  • [MeSH-major] Cystadenoma / metabolism. Follicle Stimulating Hormone / metabolism. Ovarian Cysts / metabolism. Ovarian Neoplasms / metabolism

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cysts.
  • Hazardous Substances Data Bank. MENOTROPINS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18386461.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 9002-68-0 / Follicle Stimulating Hormone
  •  go-up   go-down


49. Liu L, Sun L, Wang J, Ji G, Chen B, Zhang H: Ovarian cystadenocarcinoma and pseudomyxoma peritonei. BMJ Case Rep; 2010;2010
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian cystadenocarcinoma and pseudomyxoma peritonei.
  • BACKGROUND: Mucoceles resulting from cystadenomas of the ovary are uncommon.
  • This report concerns an unusual and interesting case of the right ovary associated with liver, spleen and kidney cysts.
  • CASE PRESENTATION: A case of ruptured mucocele resulting from cystadenoma of the ovary occurred in a 63-year-old woman.
  • Localised pseudomyxoma peritonei associated with adenocarcinoma of the right ovary was diagnosed.
  • The patient underwent resection of the ovary, uterus, uterine tube and appendix with excision of the mesenteric lymph nodes and removal of about 5000 ml of yellowish mucoid jelly.
  • CONCLUSIONS: Pseudomyxoma peritonei may occur in patients with ovarian cystadenocarcinoma.
  • In such patients, the ovary should be investigated and transvaginal ultrasound can be carefully performed in cases of ruptured mucoceles and localised pseudomyxoma peritonei.
  • [MeSH-major] Cystadenocarcinoma / pathology. Cystadenocarcinoma / surgery. Mucocele / secondary. Mucocele / surgery. Ovarian Neoplasms / pathology. Ovarian Neoplasms / surgery. Peritoneal Neoplasms / secondary. Peritoneal Neoplasms / surgery. Pseudomyxoma Peritonei / pathology. Pseudomyxoma Peritonei / surgery

  • Genetic Alliance. consumer health - Pseudomyxoma peritonei.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Surg. 2003 Jun;138(6):585-9; discussion 589-90 [12799327.001]
  • [Cites] Tech Coloproctol. 2004 Aug;8(2):109-12 [15309649.001]
  • [Cites] Int J Gynecol Cancer. 2008 Sep-Oct;18(5):916-20 [18248391.001]
  • [Cites] J Exp Clin Cancer Res. 2003 Dec;22(4 Suppl):35-9 [16767904.001]
  • [Cites] Br J Surg. 2006 Oct;93(10):1270-6 [16838392.001]
  • [Cites] Surg Today. 1995;25(8):745-9 [8520171.001]
  • [Cites] Clin Radiol. 2002 Jul;57(7):608-13 [12096860.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2003 Apr;15(2):73-7 [12708714.001]
  • [Cites] BMC Gastroenterol. 2006;6:32 [17074081.001]
  • [Cites] Arch Gynecol Obstet. 2008 Sep;278(3):265-7 [18293005.001]
  • [Cites] Abdom Imaging. 2000 May-Jun;25(3):311-6 [10823458.001]
  • (PMID = 22753161.001).
  • [ISSN] 1757-790X
  • [Journal-full-title] BMJ case reports
  • [ISO-abbreviation] BMJ Case Rep
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ PMC3029120
  •  go-up   go-down


50. Iwasaki M, Taira K, Kobayashi H, Saiga T: Ovarian mucinous cystadenoma of borderline malignancy in a premenarchal girl. J Pediatr Adolesc Gynecol; 2010 Jun;23(3):e119-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian mucinous cystadenoma of borderline malignancy in a premenarchal girl.
  • Ovarian mucinous cystadenomas are benign epithelial neoplasms that occur most often in the third to sixth decade of life.
  • Ovarian mucinous cystadenoma can be classified into 3 categories (benign, borderline malignancy, malignancy) based on histopathologic evaluation.
  • Premenarchal cases of ovarian mucinous cystadenoma of borderline malignancy are exceedingly rare.
  • To the best of our knowledge, there have been only 4 reported cases of borderline ovarian mucinous cystadenoma prior to 2009.
  • [MeSH-major] Cystadenoma, Mucinous / pathology. Cystadenoma, Mucinous / ultrasonography. Ovarian Neoplasms / pathology. Ovarian Neoplasms / ultrasonography

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 North American Society for Pediatric and Adolescent Gynecology. Published by Elsevier Inc. All rights reserved.
  • (PMID = 19896401.001).
  • [ISSN] 1873-4332
  • [Journal-full-title] Journal of pediatric and adolescent gynecology
  • [ISO-abbreviation] J Pediatr Adolesc Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


51. Hariri LP, Bonnema GT, Schmidt K, Winkler AM, Korde V, Hatch KD, Davis JR, Brewer MA, Barton JK: Laparoscopic optical coherence tomography imaging of human ovarian cancer. Gynecol Oncol; 2009 Aug;114(2):188-94
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic optical coherence tomography imaging of human ovarian cancer.
  • OBJECTIVES: Ovarian cancer is the fourth leading cause of cancer-related death among women in the US largely due to late detection secondary to unreliable symptomology and screening tools without adequate resolution.
  • Optical coherence tomography (OCT) is a recently emerging imaging modality with promise in ovarian cancer diagnostics, providing non-destructive subsurface imaging at imaging depths up to 2 mm with near-histological grade resolution (10-20 microm).
  • OCT images were compared with histopathology to identify preliminary architectural imaging features of normal and pathologic ovarian tissue.
  • RESULTS: Thirty ovaries in 17 primarily peri- or post-menopausal women were successfully imaged with LOCT: 16 normal, 5 endometriosis, 3 serous cystadenoma, and 4 adenocarcinoma.
  • Preliminary imaging features developed for each category reveal qualitative differences in the homogeneous character of normal post-menopausal ovary, the ability to image small subsurface inclusion cysts, and distinguishable features for endometriosis, cystadenoma, and adenocarcinoma.
  • Comparison of OCT images and corresponding histopathology allowed for the description of preliminary microstructural features for normal ovary, endometriosis, and benign and malignant surface epithelial neoplasms.
  • These results support the potential of OCT both as a diagnostic tool and an imaging modality for further evaluation of ovarian cancer pathogenesis.
  • [MeSH-major] Optics and Photonics / methods. Ovarian Neoplasms / diagnosis. Tomography / methods

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2000 Jul;18(14):2728-32 [10894872.001]
  • [Cites] Obstet Gynecol. 2009 Apr;113(4):775-82 [19305319.001]
  • [Cites] Med Electron Microsc. 2003 Mar;36(1):9-17 [12658347.001]
  • [Cites] J Biomed Opt. 2003 Jul;8(3):570-5 [12880366.001]
  • [Cites] Int J Gynecol Cancer. 2004 May-Jun;14(3):470-4 [15228420.001]
  • [Cites] Obstet Gynecol. 1999 Jan;93(1):135-9 [9916971.001]
  • [Cites] Br J Obstet Gynaecol. 1999 Oct;106(10):1071-7 [10519434.001]
  • [Cites] Technol Cancer Res Treat. 2004 Dec;3(6):617-27 [15560720.001]
  • [Cites] J Clin Oncol. 2005 Jan 1;23(1):127-32 [15625367.001]
  • [Cites] Am J Obstet Gynecol. 2005 Jul;193(1):83-8 [16021063.001]
  • [Cites] J Biomed Opt. 2006 Mar-Apr;11(2):021002 [16674177.001]
  • [Cites] Int J Gynecol Cancer. 2006 Sep-Oct;16(5):1815-22 [17009977.001]
  • [Cites] Curr Opin Obstet Gynecol. 2007 Feb;19(1):22-6 [17218847.001]
  • [Cites] Recent Results Cancer Res. 2007;174:91-100 [17302189.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2007 Dec;48(12):5339-51 [18055780.001]
  • [Cites] Dis Markers. 2007;23(5-6):397-410 [18057523.001]
  • [Cites] Int J Gynecol Pathol. 2008 Apr;27(2):151-60 [18317228.001]
  • [Cites] Catheter Cardiovasc Interv. 2008 Aug 1;72(2):237-47 [18655155.001]
  • [Cites] Am J Obstet Gynecol. 2008 Sep;199(3):215-23 [18468571.001]
  • [Cites] Gastrointest Endosc. 2008 Oct;68(4):745-53 [18926183.001]
  • [Cites] Int Ophthalmol Clin. 2008 Fall;48(4):29-45 [18936635.001]
  • [Cites] World J Gastroenterol. 2008 Nov 14;14(42):6444-52 [19030194.001]
  • [Cites] Gynecol Oncol. 2002 Oct;87(1):52-6 [12468342.001]
  • (PMID = 19481241.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Grant] United States / NHLBI NIH HHS / HL / T32 HL007955; United States / NHLBI NIH HHS / HL / T32 HL007955-11A1
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS281007; NLM/ PMC3073086
  •  go-up   go-down


52. Wen YH, Yee H, Goswami S, Shukla PS: Fascin expression in serous tumors of ovary correlates with aggressiveness of malignancy. Int J Gynecol Pathol; 2009 Mar;28(2):187-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fascin expression in serous tumors of ovary correlates with aggressiveness of malignancy.
  • Ovarian serous tumors make up about one-fourth of all ovarian tumors.
  • There is a spectrum of proliferation and cellular atypia in these tumors with benign serous cystadenoma, borderline tumors, and low grade or type I serous carcinoma at the lower end and type II or high-grade serous papillary cystadenocarcinoma at the higher end.
  • The aim of this study was to investigate fascin expression in serous tumors of ovary and to evaluate its relationship with the aggressiveness of tumor.
  • Sections from a total of 66 serous tumors of ovary were collected including 26 serous carcinomas, 20 borderline serous tumors, and 20 benign serous cystadenomas.
  • Ten benign ovaries with inclusion cysts were used as controls.
  • Fascin expression was significantly increased in borderline (13/20, 65%) and malignant serous tumors (22/26, 84%) compared with benign serous cystadenoma (0/20) (P<0.001).
  • Our findings suggest that upregulation of fascin plays a role in increasing aggressiveness of serous ovarian tumors and could potentially be a molecular therapeutic target and a prognostic marker.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carrier Proteins / biosynthesis. Cystadenocarcinoma, Serous / pathology. Microfilament Proteins / biosynthesis. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19188814.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carrier Proteins; 0 / Microfilament Proteins; 146808-54-0 / fascin
  •  go-up   go-down


53. Zhang WY, Pan Y, Zhu LR, Zhang JZ, Zhang M, Feng K, Zhou L, Yu L, Zhang XM, Ng SW: [Expression of topoisomerase III alpha in epithelial ovarian tumors of different types and relation between the expression of topoisomerase III alpha and the clinical pathology of tumor]. Zhonghua Yi Xue Za Zhi; 2005 Nov 9;85(42):2988-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of topoisomerase III alpha in epithelial ovarian tumors of different types and relation between the expression of topoisomerase III alpha and the clinical pathology of tumor].
  • OBJECTIVE: To investigate the expression status of topoisomerase IIIa in epithelial ovarian tumor and the relationship between the expression status of topoisomerase IIIa and pathological type and clinical stage of epithelial ovarian carcinoma.
  • METHODS: Immunohistochemistry was carried out in the samples of ovarian tumor obtained during operation from 169 patients, aged 28 approximately 59, 18 cases with serous cystadenoma, 30 cases with serous borderline cystadenoma, 37 serous cystadenocarcinoma, 10 cases with mucous cystadenoma, 20 mucous borderline cystadenoma, 26 mucous cystadenocarcinoma, 19 cases with endometrial carcinoma of ovary, and 9 cases with clear cell carcinoma.
  • RESULTS: The expression rate of topoisomerase IIIa was 17.9% in the benign ovarian tumors, 74.0% in the borderline cystadenoma, and 42.7% in the malignant tumors with statistical significance among them (chi(2) = 24.657, P < 0.001).
  • CONCLUSION: Topoisomerase IIIa is highly expressed in epithelial ovarian carcinoma, and its expression level is correlated with the character and type of tumor tissues.
  • [MeSH-major] DNA Topoisomerases, Type I / biosynthesis. Ovarian Neoplasms / enzymology
  • [MeSH-minor] Adult. Cystadenoma, Mucinous / enzymology. Cystadenoma, Mucinous / pathology. Cystadenoma, Serous / enzymology. Cystadenoma, Serous / pathology. Female. Humans. Immunohistochemistry. Isoenzymes / biosynthesis. Middle Aged. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16324386.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Isoenzymes; EC 5.99.1.2 / DNA Topoisomerases, Type I; EC 5.99.1.2 / DNA topoisomerase III
  •  go-up   go-down


54. Katz L, Levy A, Wiznitzer A, Sheiner E: Pregnancy outcome of patients with dermoid and other benign ovarian cysts. Arch Gynecol Obstet; 2010 May;281(5):811-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pregnancy outcome of patients with dermoid and other benign ovarian cysts.
  • OBJECTIVE: To investigate pregnancy outcome of patients with dermoid and other benign ovarian cysts.
  • METHODS: A population-based study comparing all pregnancies of women with and without benign ovarian cysts was conducted.
  • A multivariate logistic regression model, with backward elimination, was constructed to find independent risk factors associated with benign ovarian cysts.
  • RESULTS: During the study period there were 212,114 deliveries, of which 93 occurred in patients with benign ovarian cysts.
  • Most of the lesions were benign cyatadenoma (41.9%), 36.7% were dermoid cyst, and 11.8% were adenofibroma, mostly diagnosed during cesarean delivery (76.3%).
  • The mean diameter at diagnosis was 9.05+/-7.6 cm for cystadenoma, 6.09+/-3.0 cm for dermoid cyst and 4.55+/-4.1 cm for adenofibroma.
  • Only 3 cases of ovarian torsion were noted (3.2%), and 15 cases of hospitalization due to abdominal pain (16.2%).
  • The following conditions were significantly associated with benign ovarian cysts: hypertensive disorder [odds ratio (OR) 3.05; 95% confidence interval (CI) 1.87-4.97], and maternal age (OR 1.04; 95% CI 1.01-1.07).
  • Ovarian dermoid cyst was significantly associated with fertility treatments (8.6 vs. 2.4% OR=3.75; 95% CI 1.1-12.2; P=0.019).
  • In addition, after controlling for maternal age using a multivariate analysis, fertility treatments remained significantly associated with ovarian dermoid.
  • CONCLUSION: The course of pregnancy of patients with dermoid and other benign ovarian cysts, including perinatal outcomes, is favorable.
  • [MeSH-major] Dermoid Cyst / epidemiology. Ovarian Cysts / epidemiology. Ovarian Neoplasms / epidemiology. Pregnancy Complications / epidemiology


55. Hua K, Feng W, Cao Q, Zhou X, Lu X, Feng Y: Estrogen and progestin regulate metastasis through the PI3K/AKT pathway in human ovarian cancer. Int J Oncol; 2008 Nov;33(5):959-67
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Estrogen and progestin regulate metastasis through the PI3K/AKT pathway in human ovarian cancer.
  • Estrogen and progestin are involved in ovarian carcinogenesis.
  • Change in nm23-H1 expression and the PIK3/AKT pathway are involved in carcinogenesis, development, invasion and metastasis of ovarian cancers.
  • Therefore, it is critical to understand the signaling pathways that regulate hormone-induced cell migration and invasion in ovarian cancer.
  • We investigated nm23-H1, AKT and pAKT expression by using immunohistochemical staining in ovarian clear cell adenocarcinoma, ovarian benign, borderline and malignant serous tumors and analyzed their relationship with prognostic factors.
  • Using ES-2 and SKOV-3 ovarian cancer cell lines, we studied the modulation of estrogen and progestin on cell migration and invasion as well as their effect on AKT, pAKT and nm23-H1 expression.
  • Weak nm23-H1 and high AKT and pAKT expression was observed in ovarian serous adeno-carcinoma and ovarian clear cell adenocarcinoma.
  • Our data suggest that AKT and pAKT are unfavorable prognostic factors for ovarian serous adenocarcinoma and clear cell carcinomas whereas nm23-H1 expression predicates favorable patient prognosis.
  • [MeSH-major] Adenocarcinoma / enzymology. Antineoplastic Agents, Hormonal / pharmacology. Cystadenoma, Serous / enzymology. Estrogens / metabolism. Ovarian Neoplasms / enzymology. Phosphatidylinositol 3-Kinases / metabolism. Progestins / pharmacology. Proto-Oncogene Proteins c-akt / metabolism

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18949358.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Estrogens; 0 / NM23 Nucleoside Diphosphate Kinases; 0 / Progestins; 0 / Protein Kinase Inhibitors; 0 / RNA, Small Interfering; C2QI4IOI2G / Medroxyprogesterone Acetate; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 2.7.4.6 / NME1 protein, human
  •  go-up   go-down


56. Dørum A, Blom GP, Ekerhovd E, Granberg S: Prevalence and histologic diagnosis of adnexal cysts in postmenopausal women: an autopsy study. Am J Obstet Gynecol; 2005 Jan;192(1):48-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Ovarian cysts were found in 36 of the women (15.4%).
  • Nine women (3.8%) had ovarian cysts with a diameter between 20 and < or =50 mm; 4 women (1.7%) had cysts that were >50 mm in diameter.
  • Four women had bilateral ovarian cysts.
  • All cysts were benign, except for 1 woman, who had bilateral serous cystadenoma of borderline type.
  • CONCLUSION: Because of the high prevalence of benign adnexal cysts, the identification of small unilocular cysts in postmenopausal women should be regarded as a normal finding.
  • [MeSH-major] Ovarian Cysts / epidemiology

  • MedlinePlus Health Information. consumer health - Ovarian Cysts.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15672002.001).
  • [ISSN] 0002-9378
  • [Journal-full-title] American journal of obstetrics and gynecology
  • [ISO-abbreviation] Am. J. Obstet. Gynecol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


57. Yi SW: Two-port laparoscopic adnexal surgery with a multichannel port using a wound retractor: is it safe and minimally scarring? J Laparoendosc Adv Surg Tech A; 2009 Dec;19(6):781-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A series of patients undergoing two-port laparoscopy for a benign pelvic mass were enrolled in this study.
  • The operative procedures were adnexectomy (n = 8), myomectomy (n = 1), and ovarian cystectomy and/or salpingectomy (n = 10).
  • The pathologic diagnosis were mature cystic teratoma (n = 6), benign cyst (n = 4), endometrial cyst (n = 3), serous cystadenoma (n = 3), mucinous cystadenoma (n = 1), leiomyoma (n = 1), and tubo-ovarian abscess (n = 1).

  • MedlinePlus Health Information. consumer health - Scars.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19694570.001).
  • [ISSN] 1557-9034
  • [Journal-full-title] Journal of laparoendoscopic & advanced surgical techniques. Part A
  • [ISO-abbreviation] J Laparoendosc Adv Surg Tech A
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


58. McBroom JW, Acs G, Rose GS, Krivak TC, Mohyeldin A, Verma A: Erythropoietin receptor function and expression in epithelial ovarian carcinoma. Gynecol Oncol; 2005 Dec;99(3):571-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Erythropoietin receptor function and expression in epithelial ovarian carcinoma.
  • OBJECTIVE: Our objectives were to determine if the erythropoietin receptor (EpoR) has increased expression in epithelial ovarian carcinoma, and if erythropoietin (Epo) confers malignant properties to ovarian cancer cell lines.
  • METHODS: A Western blot analysis of protein lysates from normal ovarian surface epithelial cells and ovarian cancer cell lines was performed.
  • In addition, immunohistochemical (IHC) staining for EpoR in tissue specimens of normal, low malignant potential tumor, and epithelial ovarian carcinoma was performed.
  • Epo effect on ovarian cancer cell lines was investigated by a cytotoxicity assay using a cell line with high (OVCAR3) and low (SKOV3) EpoR expression.
  • RESULTS: Western blot analysis revealed increased expression of EpoR in multiple ovarian cancer cell lines.
  • IHC staining revealed limited EpoR expression in benign ovarian tissue and increased levels in ovarian low malignant potential (LMP) tumor and carcinoma.
  • This difference between benign ovarian tissue and carcinoma was found to be statistically significant using a quantitative scoring system.
  • CONCLUSION: Increased EpoR expression in ovarian LMP tumors and carcinoma is demonstrated by Western blot analysis and IHC staining.
  • Furthermore, adversely effects sensitivity to cisplatin in the ovarian cancer cell lines.
  • [MeSH-major] Ovarian Neoplasms / metabolism. Receptors, Erythropoietin / physiology
  • [MeSH-minor] Antineoplastic Agents / pharmacology. Blotting, Western. Cell Line, Tumor. Cisplatin / pharmacology. Cystadenocarcinoma, Serous / metabolism. Cystadenocarcinoma, Serous / pathology. Cystadenoma, Serous / metabolism. Cystadenoma, Serous / pathology. Drug Screening Assays, Antitumor. Epithelial Cells / metabolism. Epithelial Cells / pathology. Female. Humans. Immunohistochemistry

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16051335.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Receptors, Erythropoietin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


59. Wang CJ, Chao A, Lai CH, Huang SY, Lee CL, Soong YK: Laparoscopically assisted vaginal ovarian cystectomy for clinically diagnosed benign large ovarian masses. J Laparoendosc Adv Surg Tech A; 2009 Oct;19(5):623-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopically assisted vaginal ovarian cystectomy for clinically diagnosed benign large ovarian masses.
  • OBJECTIVE: The aim of this study was to present our experience with laparoscopically assisted vaginal ovarian cystectomy (LAVOC) in selected patients with various large ovarian masses.
  • MATERIALS AND METHODS: Among the medical records of 324 patients with ovarian masses, 10 consecutive women of reproductive age with prior sexual activity and with large ovarian masses (10-27 cm) were evaluated.
  • A combined laparoscopic and vaginal ovarian cystectomy was done through the posterior cul-de-sac.
  • RESULTS: All operations proceeded smoothly; the ovarian pathologies included 1 mucinous cystadenoma, 1 serous cystadenoma, 1 mucinous cystadenoma coexisting with mature cystic teratoma, and 7 mature cystic teratomas.
  • [MeSH-major] Cystadenoma / surgery. Gynecologic Surgical Procedures / methods. Ovarian Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Cystadenoma, Mucinous / surgery. Cystadenoma, Serous / surgery. Female. Humans. Laparoscopy. Young Adult

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19715487.001).
  • [ISSN] 1557-9034
  • [Journal-full-title] Journal of laparoendoscopic & advanced surgical techniques. Part A
  • [ISO-abbreviation] J Laparoendosc Adv Surg Tech A
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


60. Sri Paran T, Mortell A, Devaney D, Pinter A, Puri P: Mucinous cystadenoma of the ovary in perimenarchal girls. Pediatr Surg Int; 2006 Mar;22(3):224-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucinous cystadenoma of the ovary in perimenarchal girls.
  • Ovarian masses in children are an uncommon occurrence.
  • Mucinous tumours of the ovary occur principally in middle adult life and are extremely rare prior to menarche.
  • To the best of our knowledge, there are only 13 previous cases of benign mucinous cystadenoma (MCA) of the ovary in perimenarchal girls reported in the literature.
  • We reviewed the charts of six patients who presented with large MCA of the ovary.
  • Laparotomy revealed a tumour arising from the left ovary in five patients and from the right ovary in one.
  • Histology revealed benign MCA of the ovary in all cases.
  • MCA in perimenarchal girls usually affects the left ovary.
  • [MeSH-major] Cystadenoma, Mucinous / epidemiology. Menarche. Ovarian Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pathol Annu. 1992;27 Pt 2:281-356 [1316599.001]
  • [Cites] Am J Obstet Gynecol. 1965 Nov 15;93(6):850-66 [4284808.001]
  • [Cites] J Clin Ultrasound. 1990 May;18(4):359-63 [2161005.001]
  • [Cites] J Pediatr Surg. 2003 Mar;38(3):331-5; discussion 331-5 [12632344.001]
  • [Cites] Eur J Radiol. 1993 Nov;17 (3):159-65 [8293741.001]
  • [Cites] J Pediatr Surg. 1992 Apr;27(4):480-4 [1326038.001]
  • [Cites] Ann Chir Gynaecol Fenn Suppl. 1971;177:1-66 [4333640.001]
  • [Cites] South Med J. 1982 Oct;75(10):1265-7 [7123301.001]
  • [Cites] Clin Obstet Gynecol. 1977 Sep;20(3):607-23 [196802.001]
  • [Cites] J Obstet Gynaecol. 2004 Jan;24(1):93-4 [14675997.001]
  • [Cites] Ugeskr Laeger. 2001 Nov 19;163(47):6601-2 [11760544.001]
  • [Cites] Arch Surg. 1993 Aug;128(8):849-53; discussion 853-4 [8343057.001]
  • [Cites] Gynecol Oncol. 1992 May;45(2):219-24 [1592292.001]
  • [Cites] Cancer. 1985 May 1;55(9):1958-62 [2983869.001]
  • [Cites] J Pediatr Adolesc Gynecol. 1999 Feb;12(1):27-9 [9929837.001]
  • [Cites] J Med Assoc Thai. 2004 Feb;87(2):113-8 [15061292.001]
  • [Cites] Rev Med Brux. 2000 Jun;21(3):157-9 [10925597.001]
  • [Cites] Cancer. 1973 May;31(5):1031-45 [4735836.001]
  • [Cites] J Chir (Paris). 1993 Dec;130(12 ):525-8 [8163617.001]
  • [Cites] J Pediatr Surg. 2001 Jun;36(6):E6 [11381449.001]
  • [Cites] South Med J. 1988 Apr;81(4):464-8 [2833818.001]
  • [Cites] Gynecol Oncol. 1984 Nov;19(3):290-7 [6500373.001]
  • [Cites] Eur J Pediatr Surg. 2002 Oct;12(5):330-2 [12469261.001]
  • [Cites] Cancer. 1972 Sep;30(3):713-9 [4342408.001]
  • [Cites] J Pediatr Surg. 2001 Mar;36(3):511-5 [11227010.001]
  • (PMID = 16416281.001).
  • [ISSN] 0179-0358
  • [Journal-full-title] Pediatric surgery international
  • [ISO-abbreviation] Pediatr. Surg. Int.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


61. Kabukcuoglu S, Oner U, Ozalp SS, Bildirici K, Yalcin OT, Colak E: The role of actin bundling protein fascin in the progression of ovarian neoplasms. Eur J Gynaecol Oncol; 2006;27(2):171-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of actin bundling protein fascin in the progression of ovarian neoplasms.
  • PURPOSE OF INVESTIGATION: The aim of the study was to investigate the role of fascin in tumor progression and to investigate the role of fascin on endothelial cell migration and angiogenesis in ovarian neoplasms.
  • METHODS: In the study, 94 malign epithelial ovarian neoplasms, 13 borderline epithelial ovarian neoplasms, 25 serous and mucinous cystadenomas and four normal ovarian tissues were examined by means of immunohistochemistry, using monoclonal antihuman fascin antibody, clone IM20.
  • RESULTS: Total stromal fascin score in cases of borderline and malign epithelial ovarian tumors was significantly higher compared to normal ovaries and benign epithelial ovarian tumors (.000, p < 0.001).
  • There was no significant difference in terms of mean microvessel count and homogeneous or heterogeneous fascin expression of microvessels between the benign and malign groups (respectively p = .228 and p = .143).
  • CONCLUSIONS: This study suggests that up-regulation of fascin in tumoral tissue may promote invasion of ovarian carcinoma by cell-matrix adhesion.
  • [MeSH-major] Actins / metabolism. Carrier Proteins / metabolism. Cystadenoma, Mucinous / metabolism. Cystadenoma, Mucinous / pathology. Cystadenoma, Mucinous / surgery. Microfilament Proteins / metabolism. Ovarian Neoplasms / metabolism. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16620064.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Actins; 0 / Antibodies, Monoclonal; 0 / Carrier Proteins; 0 / Microfilament Proteins; 146808-54-0 / fascin
  •  go-up   go-down


62. Massicot R, Rousseau V, Darwish AA, Sauvat F, Jaubert F, Nihoul-Fékété C: Serous and seromucinous infantile ovarian cystadenomas--a study of 42 cases. Eur J Obstet Gynecol Reprod Biol; 2009 Jan;142(1):64-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serous and seromucinous infantile ovarian cystadenomas--a study of 42 cases.
  • The rarity of infantile ovarian cystadenoma (CA) accounts for the very little knowledge about their behaviour.
  • The aim of this retrospective study is to highlight the modes of presentation and to evaluate the treatments and the recurrence risks of these benign tumours.
  • Relation to adult epithelial ovarian tumours is discussed.
  • Mucinous cystadenomas (MCA) are better described as seromucinous cystadenoma (SMCA) because of the mucinous cells localisation.
  • Complete removal of these potentially low-grade malignant ovarian tumours precursors is advocated.
  • Conservative surgery is recommended to preserve ovarian function.
  • [MeSH-major] Cystadenoma / pathology. Cystadenoma, Mucinous / pathology. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18996636.001).
  • [ISSN] 1872-7654
  • [Journal-full-title] European journal of obstetrics, gynecology, and reproductive biology
  • [ISO-abbreviation] Eur. J. Obstet. Gynecol. Reprod. Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


63. Chen M, Wang WC, Zhou C, Zhou NN, Cai K, Yang ZH, Zhao WF, Li SY, Li GZ: Differentiation between malignant and benign ovarian tumors by magnetic resonance imaging. Chin Med Sci J; 2006 Dec;21(4):270-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differentiation between malignant and benign ovarian tumors by magnetic resonance imaging.
  • OBJECTIVE: To determine the magnetic resonance (MR) imaging findings of an ovarian mass which are most predictive of malignancy and assess the value of intravenous gadolinium administration in the characterization of an ovarian mass.
  • Total 70 ovarian masses were detected by contrast-enhanced MR imaging including 37 malignant ovarian masses and 33 benign ovarian masses with 87% (61/70) accuracy, 86% (32/37) sensitivity, 88% (29/33) specificity, 89% (32/36) positive predictive value, and 85% (29/34) negative predictive value, whereas 70 ovarian masses were detected by unenhanced MR imaging with 74% (52/70) accuracy, 73% (27/37) sensitivity, 76% (25/33) specificity, 77% (27/35) positive predictive value, and 71% (25/35) negative predictive value.

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17249204.001).
  • [ISSN] 1001-9294
  • [Journal-full-title] Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih
  • [ISO-abbreviation] Chin. Med. Sci. J.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] China
  •  go-up   go-down


64. Kolluru V, Gurumurthy R, Vellanki V, Gururaj D: Torsion of ovarian cyst during pregnancy: a case report. Cases J; 2009;2:9405
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Torsion of ovarian cyst during pregnancy: a case report.
  • In this case we report a 23 -year-old primigravida with 30 weeks presenting with torsion of the ovarian cyst.
  • She was diagnosed to have torsion of ovarian cyst during pregnancy and a cystecomy was carried out.
  • Her histopathology report showed a benign serous cystadenoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Fertil Steril. 2009 May;91(5):1895-902 [18359024.001]
  • [Cites] Obstet Gynecol. 2005 May;105(5 Pt 1):1098-103 [15863550.001]
  • [Cites] Eur J Gynaecol Oncol. 2002;23(2):133-4 [12013110.001]
  • [Cites] Int J Gynaecol Obstet. 1989 Jan;28(1):21-5 [2565826.001]
  • [Cites] Am J Obstet Gynecol. 1985 Jun 15;152(4):456-61 [4014339.001]
  • [Cites] Am J Obstet Gynecol. 1999 Jul;181(1):19-24 [10411786.001]
  • (PMID = 20090873.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2809077
  •  go-up   go-down


65. Pan Y, Jiao J, Zhou C, Cheng Q, Hu Y, Chen H: Nanog is highly expressed in ovarian serous cystadenocarcinoma and correlated with clinical stage and pathological grade. Pathobiology; 2010;77(6):283-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nanog is highly expressed in ovarian serous cystadenocarcinoma and correlated with clinical stage and pathological grade.
  • We investigated whether the Nanog expression is associated with the occurrence and development of ovarian cancer.
  • METHODS: Immunohistochemistry was used to examine the expression of Nanog in 43 normal ovarian epithelia, 110 serous cystadenomas, 80 borderline serous cystadenomas, and 107 serous cystadenocarcinomas.
  • RESULTS: The expression intensity of Nanog in normal ovarian tissue, benign, borderline, and malignant tumors showed a gradual rising trend.
  • CONCLUSIONS: Nanog was highly expressed in ovarian serous cystadenocarcinoma, and showed a positive correlation with clinical stage and grade.
  • Nanog may play an important role in the development of dedifferentiation and progression of serous ovarian carcinoma.
  • [MeSH-major] Cystadenocarcinoma, Serous / metabolism. Cystadenocarcinoma, Serous / pathology. Homeodomain Proteins / metabolism. Ovarian Neoplasms / metabolism. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adult. Cell Dedifferentiation. Cystadenoma, Serous / metabolism. Cystadenoma, Serous / pathology. Female. Humans. Immunohistochemistry. Middle Aged. Neoplasm Staging. Ovary / metabolism

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2011 S. Karger AG, Basel.
  • (PMID = 21266826.001).
  • [ISSN] 1423-0291
  • [Journal-full-title] Pathobiology : journal of immunopathology, molecular and cellular biology
  • [ISO-abbreviation] Pathobiology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Homeodomain Proteins; 0 / NANOG protein, human
  •  go-up   go-down


66. Kassab A, El-Bialy G, Clark J, Callen P, Powari M, Jones H: Unusual presentation of 22-kilogram retroperitoneal müllerian serous cystadenoma. Gynecol Oncol; 2007 Jan;104(1):257-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unusual presentation of 22-kilogram retroperitoneal müllerian serous cystadenoma.
  • It is a benign condition that can only be diagnosed and cured by surgical resection.
  • CASE: An 80-year-old female with a huge cystic swelling, thought to be ovarian in origin, underwent laparotomy.
  • Surgical exploration and subsequent histopathological analysis of the cyst revealed a müllerian serous cystadenoma of the retroperitoneum, 22 kg in weight.
  • [MeSH-major] Cystadenoma, Serous / diagnosis. Cysts / diagnosis. Mullerian Ducts / pathology. Retroperitoneal Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17079007.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


67. Brun JL, Cortez A, Commo F, Uzan S, Rouzier R, Daraï E: Serous and mucinous ovarian tumors express different profiles of MMP-2, -7, -9, MT1-MMP, and TIMP-1 and -2. Int J Oncol; 2008 Dec;33(6):1239-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serous and mucinous ovarian tumors express different profiles of MMP-2, -7, -9, MT1-MMP, and TIMP-1 and -2.
  • A tissue microarray was set up including 99 serous (25 benign, 27 borderline, 47 malignant) and 79 mucinous (25 benign, 44 borderline, 10 malignant) ovarian tumors.
  • Alterations in MT1-MMP, MMP-7 and -9 were found in malignant serous tumors, while benign and borderline tumors shared similar expressions.
  • In conclusion, our results support the differential expression in MMPs and TIMPs of ovarian tumors according to serous or mucinous histology.
  • [MeSH-major] Cystadenoma, Mucinous / chemistry. Cystadenoma, Serous / chemistry. Matrix Metalloproteinases / analysis. Ovarian Neoplasms / chemistry. Tissue Inhibitor of Metalloproteinase-1 / analysis. Tissue Inhibitor of Metalloproteinase-2 / analysis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19020757.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Tissue Inhibitor of Metalloproteinase-1; 127497-59-0 / Tissue Inhibitor of Metalloproteinase-2; EC 3.4.24.- / Matrix Metalloproteinases; EC 3.4.24.23 / MMP7 protein, human; EC 3.4.24.23 / Matrix Metalloproteinase 7; EC 3.4.24.24 / MMP2 protein, human; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9; EC 3.4.24.80 / MMP14 protein, human; EC 3.4.24.80 / Matrix Metalloproteinase 14
  •  go-up   go-down


68. Handra-Luca A, Fléjou JF, Rufat P, Corcos O, Belghiti J, Ruszniewski P, Degott C, Bedossa P, Couvelard A: Human pancreatic mucinous cystadenoma is characterized by distinct mucin, cytokeratin and CD10 expression compared with intraductal papillary-mucinous adenoma. Histopathology; 2006 Jun;48(7):813-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human pancreatic mucinous cystadenoma is characterized by distinct mucin, cytokeratin and CD10 expression compared with intraductal papillary-mucinous adenoma.
  • AIMS: To examine cytokeratin, epithelial glycoprotein (mucin) and glycoprotein CD10 expression in benign mucinous cystdenomas (MCAs) in comparison with intraductal papillary mucinous adenomas (IPMAs).
  • In MCAs, CD10 was observed both in epithelial cells and in the ovarian-type stromal cells (24/30).
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Pancreatic Ductal / pathology. Cystadenoma, Mucinous / pathology. Cystadenoma, Papillary / pathology. Pancreatic Neoplasms / pathology


69. Van Holsbeke C, Van Calster B, Guerriero S, Savelli L, Leone F, Fischerova D, Czekierdowski A, Fruscio R, Veldman J, Van de Putte G, Testa AC, Bourne T, Valentin L, Timmerman D: Imaging in gynaecology: How good are we in identifying endometriomas? Facts Views Vis Obgyn; 2009;1(1):7-17
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: All patients in the International Ovarian Tumor Analysis (IOTA ) studies were included for analysis.
  • RESULTS: IOTA phase 1, 1b and 2 included 3511 patients of which 2560 were benign (73%) and 951 malignant (27%).
  • Among the 75 false positive cases, 66 were benign but 9 were malignant (5 borderline tumours, 1 rare primary invasive tumour and 3 endometrioid adenocarcinomas).
  • The presumed diagnosis suggested by the sonologist in case of a missed endometrioma was mostly functional cyst or cystadenoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 25478066.001).
  • [ISSN] 2032-0418
  • [Journal-full-title] Facts, views & vision in ObGyn
  • [ISO-abbreviation] Facts Views Vis Obgyn
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Belgium
  • [Other-IDs] NLM/ PMC4251283
  • [Keywords] NOTNLM ; Ultrasonography / adnexal tumours / endometrioma / endometriosis / pattern recognition / subjective evaluation
  •  go-up   go-down


70. Ferrero S, Ragni N, Fulcheri E: Lateral distribution of benign ovarian cysts. Int J Gynaecol Obstet; 2005 May;89(2):150-1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lateral distribution of benign ovarian cysts.
  • [MeSH-major] Ovarian Cysts / pathology
  • [MeSH-minor] Cystadenoma, Mucinous / pathology. Cystadenoma, Serous / pathology. Dermoid Cyst / pathology. Endometrium / pathology. Female. Humans. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cysts.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15847883.001).
  • [ISSN] 0020-7292
  • [Journal-full-title] International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics
  • [ISO-abbreviation] Int J Gynaecol Obstet
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


71. Ben-Ami I, Smorgick N, Tovbin J, Fuchs N, Halperin R, Pansky M: Does intraoperative spillage of benign ovarian mucinous cystadenoma increase its recurrence rate? Am J Obstet Gynecol; 2010 Feb;202(2):142.e1-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does intraoperative spillage of benign ovarian mucinous cystadenoma increase its recurrence rate?
  • OBJECTIVE: To report a higher than estimated recurrence rate of benign mucinous cystadenomas after complete resection of the first one, and to assess potential risk factors for recurrence after complete surgical excision.
  • STUDY DESIGN: We retrospectively reviewed all cases of women who underwent either laparoscopic or laparotomic removal of benign mucinous adnexal cysts by either adnexectomy or cystectomy in our institution between 1996 and 2006.
  • CONCLUSION: Mucinous cystadenoma recurrence is apparently not as rare as reported in the literature.
  • [MeSH-major] Cystadenoma, Mucinous / surgery. Neoplasm Recurrence, Local / epidemiology. Ovarian Neoplasms / surgery. Postoperative Complications / epidemiology
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Incidence. Middle Aged. Ovarian Cysts / surgery. Ovariectomy. Retrospective Studies

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Mosby, Inc. All rights reserved.
  • (PMID = 20022314.001).
  • [ISSN] 1097-6868
  • [Journal-full-title] American journal of obstetrics and gynecology
  • [ISO-abbreviation] Am. J. Obstet. Gynecol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


72. Bika O, Ola B: Complex serous cystadenoma with ovarian stroma of the fallopian tube ampulla presenting surgically. J Obstet Gynaecol; 2009 Aug;29(6):565-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complex serous cystadenoma with ovarian stroma of the fallopian tube ampulla presenting surgically.
  • [MeSH-major] Cystadenoma, Serous / pathology. Fallopian Tube Neoplasms / pathology. Fallopian Tubes / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19697223.001).
  • [ISSN] 1364-6893
  • [Journal-full-title] Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology
  • [ISO-abbreviation] J Obstet Gynaecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 5
  •  go-up   go-down


73. Seidman JD, Mehrotra A: Benign ovarian serous tumors: a re-evaluation and proposed reclassification of serous "cystadenomas" and "cystadenofibromas". Gynecol Oncol; 2005 Feb;96(2):395-401
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign ovarian serous tumors: a re-evaluation and proposed reclassification of serous "cystadenomas" and "cystadenofibromas".
  • OBJECTIVE: Serous cystadenomas and cystadenofibromas of the ovaries are currently regarded as neoplasms and are considered the most common ovarian neoplasms.
  • The purpose of this study is to determine what proportion of benign serous tumors contain an epithelial proliferation (the hallmark of a neoplastic process in nearly all other sites) that can be considered neoplastic as opposed to reactive in nature.
  • METHODS: An unselected series of 113 ovarian serous tumors (76 serous cystadenomas and 37 serous cystadenofibromas) were histologically evaluated.
  • CONCLUSION: The vast majority of benign serous tumors may not be bona fide epithelial neoplasms, but rather, may represent cystically dilated glandular inclusions (cystadenomas) and fibromas with epithelial inclusions (cystadenofibromas).
  • These findings have important implications for the pathogenesis of ovarian cancer, for the distribution of ovarian neoplasms, and for the interpretation of molecular biological studies of ovarian tumors.
  • [MeSH-major] Cystadenoma, Serous / classification. Fibroma / classification. Ovarian Neoplasms / classification

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15661227.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


74. Zhong M, Li J, Ding YQ, Song LL: [ZNF217 gene was detected in ovarian serous cystadenocarcinoma by fluorescence in situ hybridization]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2006 Dec;23(6):665-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [ZNF217 gene was detected in ovarian serous cystadenocarcinoma by fluorescence in situ hybridization].
  • OBJECTIVE: To investigate amplification of zinc finger protein 217 (ZNF217) gene in ovarian serous cystadenocarcinoma and its clinical significance.
  • METHODS: Twenty three specimens of ovarian carcinoma, 10 specimens of ovarian benign tumors and 7 specimens of normal ovaries and two ovarian cancer cell lines, SKOV3 and HO-8910 were examined by fluorescence in situ hybridization (FISH).
  • RESULTS: The amplification of ZNF217 was gained in 12 case of ovarian cancers, there was only 1 case in ovarian benign tumor and not amplication in normal ovary.
  • CONCLUSION: The amplification of ZNF217 is associated with ovarian cancer.
  • Oncogenes ZNF217 maybe play a role in cell differentiation and indicate poorer survival in patients with ovarian cancer.
  • [MeSH-major] Cystadenocarcinoma, Serous / genetics. Ovarian Neoplasms / genetics. Trans-Activators / genetics
  • [MeSH-minor] Adult. Aged. Cell Differentiation. Cell Line, Tumor. Cystadenoma, Serous / genetics. Cystadenoma, Serous / pathology. Female. Gene Amplification. Humans. In Situ Hybridization, Fluorescence. Middle Aged. Neoplasm Staging. Survival Analysis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17160949.001).
  • [ISSN] 1003-9406
  • [Journal-full-title] Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics
  • [ISO-abbreviation] Zhonghua Yi Xue Yi Chuan Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Trans-Activators; 0 / ZNF217 protein, human
  •  go-up   go-down


75. Chen ZW, Saad RS: Ovarian adenosarcoma arising from benign cystadenoma and associated intraoperative consultation pitfalls. Int J Gynecol Pathol; 2010 Sep;29(5):415-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian adenosarcoma arising from benign cystadenoma and associated intraoperative consultation pitfalls.
  • An unusual case of ovarian adenosarcoma arising from a smooth-walled serous cystadenoma is described.
  • The ovary was replaced by a multiloculated, fluid-filled cyst without any solid or papillary areas.
  • The malignant component was underdiagnosed during frozen section examination as benign cystadenoma because of the deceptively benign gross appearance of the tumor.
  • The malignant component could not be distinguished from the benign component using immunohistochemical analysis.
  • To our knowledge, this is the first reported case of an adenosarcoma arising from a grossly benign cystadenoma and the third case in the literature of an adenosarcoma associated with a cystadeno(fibro)ma.
  • This case also shows the challenges in differentiating adenosarcoma from a benign counterpart on both frozen and permanent sections.
  • [MeSH-major] Adenosarcoma / pathology. Cystadenoma / pathology. Neoplasms, Multiple Primary / pathology. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20736764.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


76. Stewart CJ, Brennan BA, Hammond IG, Leung YC, McCartney AJ: Intraoperative assessment of ovarian tumors: a 5-year review with assessment of discrepant diagnostic cases. Int J Gynecol Pathol; 2006 Jul;25(3):216-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraoperative assessment of ovarian tumors: a 5-year review with assessment of discrepant diagnostic cases.
  • Frozen section is often requested in the intraoperative assessment of patients, presenting with ovarian masses, to provide guidance for appropriate surgical management.
  • To assess the accuracy of frozen section and identify causes of diagnostic error, we reviewed 914 consecutive ovarian frozen sections performed over a 5-year period in 2 laboratories; one of which provides a general surgical pathology service and, the other, a specialist gynecologic pathology service.
  • The series included 552 benign lesions (60.4%), 96 borderline (atypical proliferating) epithelial tumors (10.5%), and 266 malignancies (29.1%).
  • This study confirms that ovarian frozen section is a generally reliable technique, but there are problematic areas, particularly involving the assessment of borderline tumors.
  • [MeSH-major] Diagnostic Errors / statistics & numerical data. Intraoperative Care / methods. Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / pathology
  • [MeSH-minor] Cystadenoma, Mucinous / diagnosis. Cystadenoma, Mucinous / pathology. Cystadenoma, Serous / diagnosis. Cystadenoma, Serous / pathology. Diagnosis, Differential. Female. Frozen Sections. Humans. Pathology, Surgical / methods. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16810056.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


77. Balci O, Gezginc K, Karatayli R, Acar A, Celik C, Colakoglu MC: Management and outcomes of adnexal masses during pregnancy: a 6-year experience. J Obstet Gynaecol Res; 2008 Aug;34(4):524-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Postoperative pathology results of the patients were functional ovarian cysts in 14 cases (41.1%), endometrioma in eight cases (23.5%), dermoid cyst in six cases (17.6%), serous cystadenoma in two cases (5.8%), mucinous cystadenoma in one case (2.9%), para-ovarian cyst in one case (2.9%), and borderline serous tumor in two cases (5.8%).
  • Most masses at pregnancies were benign in character and our malignity rate was low.

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Obstet Gynaecol Res. 2009 Jun;35(3):597-8 [19527409.001]
  • (PMID = 18946936.001).
  • [ISSN] 1341-8076
  • [Journal-full-title] The journal of obstetrics and gynaecology research
  • [ISO-abbreviation] J. Obstet. Gynaecol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


78. Han S, Xuan Y, Liu S, Zhang M, Jin D, Jin R, Lin Z: Clinicopathological significance of DEK overexpression in serous ovarian tumors. Pathol Int; 2009 Jul;59(7):443-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological significance of DEK overexpression in serous ovarian tumors.
  • To investigate the significance of DEK protein expression in ovarian lesions, a total of 113 ovarian serous tumors, including 62 serous cystadenocarcinomas and 19 serous borderline tumors, were studied on immunohistochemistry.
  • For comparison, 32 benign serous tumors, including 12 serous papillary cystadenomas, 10 serous cystadenomas, and 10 serous surface papillomas, were also included.
  • DEK was positive in 93.5% of serous cystadenocarcinomas (58/62), 63.2% of serous borderline tumors (12/19), and weakly positive in 15.6% of benign serous tumors (5/32).
  • The strong positive signal was detected only in serous adenocarcinomas (80.6%, 50/62) and borderline tumors (21.1%, 4/19), but no serous benign tumors were strongly positive (0%, 0/32).
  • Meanwhile, the strong positivity rate of DEK protein was significantly higher in grade 2 and grade 3 than in grade 1 ovarian cancers (P < 0.05), but there was no significant association between DEK protein expression level and International Federation of Gynecology and Obstetrics (FIGO) stage of serous ovarian adenocarcinoma (P > 0.05).
  • In summary, DEK plays an important role in the progression of ovarian serous cancers.
  • The detection of DEK protein expression should be useful for the diagnosis and prognosis of ovarian serous cancers, and DEK might be a useful molecular target for ovarian cancer therapy.
  • [MeSH-major] Biomarkers, Tumor / analysis. Chromosomal Proteins, Non-Histone / biosynthesis. Cystadenocarcinoma, Serous / pathology. Cystadenoma, Serous / pathology. Oncogene Proteins / biosynthesis. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19563407.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Chromosomal Proteins, Non-Histone; 0 / Dek protein, human; 0 / Oncogene Proteins
  •  go-up   go-down


79. Hu CJ, Zhang F, Chen YJ, Sun XM, Zheng JF: [Correlation of hK6 expression with clinicopathological features and prognosis in epithelial ovarian cancer]. Zhonghua Zhong Liu Za Zhi; 2009 Jul;31(7):520-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Correlation of hK6 expression with clinicopathological features and prognosis in epithelial ovarian cancer].
  • OBJECTIVE: To approach the relationship between the expression of hK6 in ovarian neoplasm and clinicopathological variables and prognosis in ovarian cancer patients for finding a new tumor marker of the ovarian cancer.
  • METHODS: The expression of hK6 was detected by immunohistochemistry in 19 cases of benign, 11 cases of borderline and 45 cases of malignant ovarian neoplasms and statistically analyzed whether its expression correlate with clinicopathological variables and prognosis in patients with ovarian cancer.
  • RESULTS: The expression of hK6 in ovarian cancer tissues (60.0%) was significantly higher than that in the benign (15.8%) and borderline (27.3%) ovarian neoplasm tissues (P < 0.01).
  • The expression of hK6 in higher-grade ovarian cancer tissues (68.4% ) was higher than that in low-grade ones (14.3%, P < 0.05).
  • CONCLUSION: The expression of hK6 in ovarian cancer was higher than that in benign and borderline ovarian neoplasms.
  • The expression of hK6 is higher in the ovarian cancer of late stage, higher-grade, with lymph node metastasis and is associated with a poorer prognosis. hK6 may become a new markers in prediction of prognosis of the patients with ovarian tumors.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Cystadenocarcinoma, Mucinous / metabolism. Cystadenocarcinoma, Serous / metabolism. Kallikreins / metabolism. Ovarian Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Carcinoma, Endometrioid / metabolism. Carcinoma, Endometrioid / pathology. Cystadenoma, Mucinous / metabolism. Cystadenoma, Mucinous / pathology. Cystadenoma, Serous / metabolism. Cystadenoma, Serous / pathology. Female. Humans. Lymphatic Metastasis. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Prognosis. Young Adult

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19950700.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.4.21.- / KLK6 protein, human; EC 3.4.21.- / Kallikreins
  •  go-up   go-down


80. Vázquez Camacho EE, Alfán Guzmán F, Carbajal Ocampo D: [Ovarian cystadenoma and ectopic pregnancy. A case report]. Ginecol Obstet Mex; 2009 Aug;77(8):387-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Ovarian cystadenoma and ectopic pregnancy. A case report].
  • [Transliterated title] Cistadenoma ovárico y embarazo ectópico concomitante. Reporte de caso.
  • A new ultrasound is made seven weeks after her last period, finding a mass in the left ovary, but without increment in beta fraction.
  • At week ten, she presents an uterine bleeding during a trip, which is diagnosed as a probable mole without any further medical treatment and from the 12th week, there is a considerable decrement in the beta fraction measure, without any other symptom, but the persistent adnexal mass at the left ovary, with irregular septum images at ultrasound.
  • A laparotomy is performed finding an ectopic pregnancy surrounded by a serum cystadenoma.
  • [MeSH-major] Cystadenoma / complications. Ovarian Neoplasms / complications. Pregnancy Complications, Neoplastic. Pregnancy, Ectopic


81. Turker O, Dogan I, Kumanlioglu K: Radioiodine accumulation in a large adnexal cystadenofibroma. Thyroid; 2010 May;20(5):561-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here we report a patient with marked radioiodine accumulation in a large adnexal cystadenofibroma, a benign ovarian tumor.
  • Pathologic examination revealed a benign cystadenofibroma without any coexisting thyroid tissue.
  • [MeSH-major] Cystadenoma / radionuclide imaging. Ovarian Neoplasms / radionuclide imaging

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20406107.001).
  • [ISSN] 1557-9077
  • [Journal-full-title] Thyroid : official journal of the American Thyroid Association
  • [ISO-abbreviation] Thyroid
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Iodine Radioisotopes
  •  go-up   go-down


82. Brustmann H: DNA fragmentation factor (DFF45): expression and prognostic value in serous ovarian cancer. Pathol Res Pract; 2006;202(10):713-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] DNA fragmentation factor (DFF45): expression and prognostic value in serous ovarian cancer.
  • This study investigated the expression of DNA fragmentation factor (DFF45), MIB-1, and p53 in formalin-fixed, paraffin-embedded archival tissues of 50 ovarian serous carcinomas.
  • In addition, 10 benign serous cystadenomas and 10 serous neoplasms of low malignant potential (LMP) were included in this DFF45 immunostudy.
  • Low DFF45 expression was identified in all serous cystadenomas and in LMPs, as well as in 18 (36%) ovarian serous carcinomas.
  • This study indicates that DFF45 expression is frequently upregulated in ovarian serous carcinomas and may serve as a marker of aggressive behavior with prognostic value.
  • [MeSH-major] Apoptosis Regulatory Proteins / metabolism. Cystadenocarcinoma, Serous / metabolism. Ovarian Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Apoptosis. Biomarkers, Tumor / metabolism. Cell Count. Cell Nucleus / metabolism. Cell Nucleus / pathology. Cell Proliferation. Cystadenoma, Serous / metabolism. Cystadenoma, Serous / pathology. Disease-Free Survival. Female. Fluorescent Antibody Technique, Direct. Humans. Immunoenzyme Techniques. Middle Aged. Neoplasm Staging. Survival Rate

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16962250.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / Biomarkers, Tumor; 0 / caspase-activated DNase inhibitor
  •  go-up   go-down


83. Gupta R, Singh S, Nigam S, Khurana N: Benign vascular tumors of female genital tract. Int J Gynecol Cancer; 2006 May-Jun;16(3):1195-200
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign vascular tumors of female genital tract.
  • The vascular tumors occurred most commonly in ovary (six), followed by vulva (two), and one each in cervix and vagina.
  • Clinical diagnoses ranged from cystadenoma in ovarian tumors to endocervical polyp in cervical tumor.
  • Histologically, all were benign vascular neoplasms, ranging from hemangioma (five), lymphangioma (one), lymphangioma circumscriptum (one) to angiomatosis (two) and arteriovenous malformation (one).
  • [MeSH-minor] Adolescent. Adult. Angiomatosis / diagnosis. Arteriovenous Malformations / diagnosis. Female. Genital Diseases, Female / diagnosis. Hemangioma / diagnosis. Humans. Lymphangioma / diagnosis. Middle Aged. Ovarian Neoplasms / diagnosis. Retrospective Studies. Uterine Cervical Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16803506.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


84. McCluggage WG, Wilkinson N: Metastatic neoplasms involving the ovary: a review with an emphasis on morphological and immunohistochemical features. Histopathology; 2005 Sep;47(3):231-47
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic neoplasms involving the ovary: a review with an emphasis on morphological and immunohistochemical features.
  • The ovary is a common site of metastatic tumour.
  • In many cases of ovarian metastasis there is a known history of malignancy but in other cases the ovarian tumour is the first manifestation of disease.
  • In this review metastatic colorectal, appendiceal, gastric, breast, pancreatic and biliary tract, hepatocellular, renal, transitional and cervical carcinomas and metastatic malignant melanoma involving the ovary are discussed, as is the issue of synchronous ovarian and endometrial carcinomas.
  • Peritoneal tumours, including primary peritoneal carcinoma, mesothelioma and intra-abdominal desmoplastic small round cell tumour, involving the ovary are also discussed, together with a variety of other rare, metastatic ovarian neoplasms.
  • Many metastatic adenocarcinomas involving the ovary, especially those exhibiting mucinous differentiation, closely mimic primary ovarian adenocarcinomas with morphologically bland areas simulating benign and borderline cystadenoma.
  • In recent years immunohistochemistry, especially but not exclusively differential cytokeratin (CK7 and CK20) staining, has been widely used as an aid to distinguish between a primary and secondary ovarian adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / secondary. Ovarian Neoplasms / secondary
  • [MeSH-minor] Female. Humans. Immunohistochemistry. Intermediate Filament Proteins / analysis. Keratin-20. Keratin-7. Keratins / analysis. Ovary / chemistry. Ovary / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16115224.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Intermediate Filament Proteins; 0 / KRT20 protein, human; 0 / KRT7 protein, human; 0 / Keratin-20; 0 / Keratin-7; 68238-35-7 / Keratins
  • [Number-of-references] 114
  •  go-up   go-down


85. Versa-Ostojić D, Stanković T, Stemberger-Papić S, Vrdoljak-Mozetic D, Manestar M, Krasević M: Nuclear morphometry and AgNOR quantification: computerized image analysis on ovarian mucinous tumor imprints. Anal Quant Cytol Histol; 2008 Jun;30(3):160-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nuclear morphometry and AgNOR quantification: computerized image analysis on ovarian mucinous tumor imprints.
  • OBJECTIVE: To determine the morphometric characteristics of nuclei and silver-stained nucleolar organizer regions (AgNORs) on cytologic imprints and their value in differential cytodiagnosis of benign, atypical proliferative (borderline) and malignant ovarian mucinous tumors.
  • STUDY DESIGN: Forty-six mucinous ovarian tumor imprints (16 benign, 15 borderline, 15 malignant), were analyzed.
  • The nuclear area in benign tumors was larger than that in borderline tumors; malignant tumors had the highest values.
  • The total AgNOR area, number and relative area increased from benign through malignant tumors, with statistically significant differences among all groups.
  • By AgNOR size distribution, small AgNORs discriminate malignant from borderline and benign tumors.
  • CONCLUSION: Combining nuclear morphometry and AgNOR analysis on cytologic imprints could be a diagnostically useful method in the assessment of mucinous ovarian tumors.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18630841.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Nuclear; 0 / nucleolar organizer region associated proteins
  •  go-up   go-down


86. Gómez-Martín C, Rodríguez A, Malón D, Cortés-Funes H: Biliary cystadenocarcinoma with mesenchymal stroma. Clin Transl Oncol; 2010 Mar;12(3):234-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This tumour needs to be distinguished from benign biliary cystadenoma, which is antecedent in most cases.
  • The diagnostic evaluation, surgical management, pathological characteristics, treatment and follow-up of one patient with hepatobiliary cystadenocarcinoma with ovarian stroma is described.
  • MRI is suitable for accurate characterisation of cystic biliary lesions, but distinguishing between cystadenoma and cystadenocarcinoma remains difficult on the basis of imaging findings.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur Radiol. 2006 Feb;16(2):407-13 [15983777.001]
  • [Cites] J Surg Oncol. 1997 Apr;64(4):341-6 [9142194.001]
  • [Cites] Cancer. 1992 Oct 1;70(7):1841-6 [1525758.001]
  • [Cites] World J Gastroenterol. 2006 Sep 21;12(35):5735-8 [17007033.001]
  • [Cites] Liver Transpl. 2000 Nov;6(6 Suppl 2):S23-9 [11084081.001]
  • [Cites] Am J Surg Pathol. 1994 Nov;18(11):1078-91 [7943529.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2006;13(6):594-9 [17139440.001]
  • [Cites] Radiology. 1995 Sep;196(3):805-10 [7644647.001]
  • [Cites] Mod Pathol. 2006 Sep;19(9):1243-54 [16741522.001]
  • [Cites] World J Gastroenterol. 2008 Jun 21;14(23):3616-20 [18595127.001]
  • [Cites] Hepatobiliary Pancreat Dis Int. 2009 Feb;8(1):71-4 [19208519.001]
  • (PMID = 20231130.001).
  • [ISSN] 1699-3055
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


87. Salani R, Neuberger I, Kurman RJ, Bristow RE, Chang HW, Wang TL, Shih IeM: Expression of extracellular matrix proteins in ovarian serous tumors. Int J Gynecol Pathol; 2007 Apr;26(2):141-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of extracellular matrix proteins in ovarian serous tumors.
  • The aims of this study were to perform a comprehensive expression analysis of the genes encoding extracellular matrix proteins and to investigate the expression pattern in one of these proteins, syndecan 1, in normal ovarian epithelium as well as benign and malignant ovarian serous tumors.
  • Gene expression of 16 different extracellular matrix proteins was analyzed in ovarian serous tumors based on serial analysis of gene expression database.
  • As compared with normal ovarian surface epithelium, we found overexpression of syndecan 1, collagen type IV alpha 2, elastin microfibril interfase located protein 1, and laminin 5 in ovarian serous carcinomas.
  • Syndecan 1 was selected for further study as it has not been well characterized in ovarian cancer and the syndecan 1 antibody was available for immunohistochemistry.
  • Using a syndecan 1-specific monoclonal antibody, we demonstrated that syndecan 1 was expressed in 30.4% of high-grade serous carcinomas, 29.7% of low-grade carcinomas and serous borderline tumors, but none of benign serous cystadenomas and ovarian surface epithelium.
  • In summary, ovarian carcinomas exhibit up-regulated expression of several extracellular matrix proteins, and syndecan 1 represents a novel tumor-associated marker in ovarian serous carcinomas.
  • [MeSH-major] Cystadenoma, Serous / metabolism. Extracellular Matrix Proteins / metabolism. Neoplasms, Cystic, Mucinous, and Serous / metabolism. Ovarian Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17413980.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Collagen Type IV; 0 / Extracellular Matrix Proteins; 0 / Laminin; 0 / Membrane Glycoproteins; 0 / Syndecan-1; 0 / elastin microfibril interface located protein
  •  go-up   go-down


88. Basic-Jukic N, Furic-Cunko V, Coric M, Bubic-Filipi LJ, Kastelan Z, Pasini J, Kes P: Appendiceal carcinoid and mucinous cystadenoma in renal transplant recipients: case reports. Transplant Proc; 2010 Jun;42(5):1704-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Appendiceal carcinoid and mucinous cystadenoma in renal transplant recipients: case reports.
  • Although appendiceal carcinoid tumors are the commonest malignant neoplasms affecting the appendix, and mucinous cystadenoma is the commonest benign appendiceal neoplasm, they have not been reported in immunosuppressed patients.
  • We present two renal transplant recipients who developed combined appendiceal carcinoid and mucinous cystadenoma.
  • [MeSH-major] Appendiceal Neoplasms / etiology. Cystadenoma, Mucinous / etiology. Kidney Transplantation / adverse effects
  • [MeSH-minor] Adult. Female. Humans. Kidney Failure, Chronic / surgery. Magnetic Resonance Imaging. Male. Neoplasms / epidemiology. Neoplasms / etiology. Neoplasms / pathology. Neoplasms / surgery. Ovarian Neoplasms / pathology. Ovarian Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20620505.001).
  • [ISSN] 1873-2623
  • [Journal-full-title] Transplantation proceedings
  • [ISO-abbreviation] Transplant. Proc.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


89. Mohammad A, Makaju R: Retrospective histopathological analysis of various neoplasms of the female reproductive system (FRS) seen at the Kathmandu University Teaching Hospital, (KUTH) Dhulikhel, Nepal. Kathmandu Univ Med J (KUMJ); 2006 Jan-Mar;4(1):48-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Out of these, 1 (1.7%) was of the vagina (squamous cell carcinoma, papillary variant); 16 (26.7%) were of the cervix of the uterus (all squamous cell carcinoma in advanced stage); none were of the endometrium; 20 (33.3%) were of the body of the uterus/uterine muscle (all liomyomas); 16 (26.7%) were of the ovary, (11 benign, consisting of nine mature cystic tertoma, also known as dermoid cyst, one serous papillary cystdenoma and one mucinous cystadenoma; and, five malignant, consisting of two serous cystadenocarcinoma, two mucinous cystadenocarcinoma and one mixed mucinous and serous cystadenocarcinoma); and, 7 (11.6%) were of the breast (two benign, consisting of fibroadenoma and five malignant, all consisting of infiltrating ductal carcinoma in advanced stage).
  • [MeSH-minor] Adenocarcinoma / pathology. Breast Neoplasms / pathology. Carcinoma, Ductal / pathology. Carcinoma, Squamous Cell / pathology. Cystadenocarcinoma / pathology. Cystadenoma / pathology. Female. Fibroadenoma / pathology. Humans. Leiomyoma / pathology. Nepal. Ovarian Neoplasms / pathology. Retrospective Studies. Uterine Cervical Neoplasms / pathology. Uterine Neoplasms / pathology. Vaginal Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18603868.001).
  • [ISSN] 1812-2027
  • [Journal-full-title] Kathmandu University medical journal (KUMJ)
  • [ISO-abbreviation] Kathmandu Univ Med J (KUMJ)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Nepal
  •  go-up   go-down


90. Shizhuo W, Tao J, Shulan Z, Bing Z: The expression and significance of Dickkopf-1 in epithelial ovarian carcinoma. Int J Biol Markers; 2009 Jul-Sep;24(3):165-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The expression and significance of Dickkopf-1 in epithelial ovarian carcinoma.
  • The aim of this study was to investigate the presence and prognostic value of Dickkopf-1 (DKK1) in epithelia ovarian carcinoma.
  • The expression of DKK1 was determined in 56 epithelial ovarian carcinoma tissues, 35 benign ovarian cystadenoma tissues, and 12 normal ovarian tissues by quantitative real-time PCR and immunohistochemistry.
  • The mRNA level of DKK1 in the cystadenoma tissues (1.1+/-0.4-fold increase) was not statistically different from that in the normal tissues (p=0.486).
  • DKK1 protein expression in the carcinoma tissues was also higher (89.29%) than in cystadenoma (65.71%) and normal tissues (58.33%) (p=0.006 and p=0.009, respectively).
  • In epithelial ovarian carcinoma, DKK1 gene and protein overexpression was associated with advanced FIGO stage (p=0.007, p=0.004) and poor differentiation grade (p=0.027, p=0.010).
  • Elevated DKK1 protein levels in ovarian carcinoma samples were associated with a poor outcome in univariate and multivariate analysis (p<0.0001 and p<0.0001, respectively).
  • The study indicated that DKK1 maymbe a useful prognostic and diagnostic indicator for epithelial ovarian carcinoma.
  • [MeSH-major] Cystadenoma / genetics. Intercellular Signaling Peptides and Proteins / genetics. Ovarian Diseases / genetics. Ovarian Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Disorders.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19787627.001).
  • [ISSN] 0393-6155
  • [Journal-full-title] The International journal of biological markers
  • [ISO-abbreviation] Int. J. Biol. Markers
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DKK1 protein, human; 0 / Intercellular Signaling Peptides and Proteins; 0 / RNA, Messenger
  •  go-up   go-down


91. Wertel I, Polak G, Bednarek W, Barczyński B, Roliński J, Kotarski J: Dendritic cell subsets in the peritoneal fluid and peripheral blood of women suffering from ovarian cancer. Cytometry B Clin Cytom; 2008 Jul;74(4):251-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dendritic cell subsets in the peritoneal fluid and peripheral blood of women suffering from ovarian cancer.
  • BACKGROUND: Evaluation of immature myeloid and lymphoid dendritic cells (DCs) in the peritoneal fluid (PF) and peripheral blood (PB) mononuclears of women with ovarian carcinoma (n = 47) and benign ovarian tumors (n = 37).
  • RESULTS: The percentage of PF myeloid DC (MDC) in mononuclears was significantly lower in patients with ovarian cancer in comparison to the group of nonmalignant ovarian tumors (0.65% and 6.95%).
  • The percentage of PF lymphoid DCs (LDCs) was higher in patients with ovarian cancer than in the reference group (0.64% and 0.09%).
  • In women suffering from ovarian cancer the percentage of both MDCs and LDCs was higher in the PF than in the PB.
  • In women with ovarian cancer, PF MDCs/LDCs ratio was lower in comparison to patients with serous cystadenoma.
  • LDC subsets may have influence on the local immune response in the PF of women with malignant tumors of the ovary. (c) 2008 Clinical Cytometry Society.
  • [MeSH-major] Ascitic Fluid / cytology. Dendritic Cells / metabolism. Ovarian Neoplasms
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cystadenoma, Serous / immunology. Cystadenoma, Serous / pathology. Disease Progression. Female. Flow Cytometry. Humans. Leukocytes, Mononuclear / immunology. Middle Aged. Neoplasm Metastasis

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18302193.001).
  • [ISSN] 1552-4957
  • [Journal-full-title] Cytometry. Part B, Clinical cytometry
  • [ISO-abbreviation] Cytometry B Clin Cytom
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


92. Khunamornpong S, Lerwill MF, Siriaunkgul S, Suprasert P, Pojchamarnwiputh S, Chiangmai WN, Young RH: Carcinoma of extrahepatic bile ducts and gallbladder metastatic to the ovary: a report of 16 cases. Int J Gynecol Pathol; 2008 Jul;27(3):366-79
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carcinoma of extrahepatic bile ducts and gallbladder metastatic to the ovary: a report of 16 cases.
  • Information on ovarian metastasis of carcinoma of the extrahepatic bile ducts and gallbladder is limited.
  • The patients ranged from 21 to 87 years (mean, 59 years); 7 presented to gynecologists with nonspecific pelvic symptoms similar to primary ovarian neoplasms.
  • The primary tumor was identified before the detection of the ovarian lesions in 5 cases, was simultaneously detected with the ovarian metastases in 9, and was diagnosed postoperatively in 2.
  • All but one case had bilateral ovarian involvement.
  • The thirty-one ovarian lesions included twenty-nine grossly abnormal ovaries that were enlarged (range, 3.0-16.5 cm, mean, 9.4 cm) and 2 ovaries with only microscopic involvement.
  • Microscopically, ovarian surface implants were seen in 66%, multinodular growth in 58%, and infiltrative stromal invasion in 81%.
  • Mucinous epithelial differentiation was seen in 81%, sometimes with foci of benign-like or borderline-like epithelium simulating primary ovarian mucinous neoplasia.
  • Cystadenoma and cystadenofibroma of nonmucinous type was even mimicked strikingly in some cases because of flattening of epithelium lining glands and cysts.
  • Although the diagnosis of a metastatic tumor to the ovary is possible in most of the cases based on standard diagnostic criteria, problems in the differential diagnosis may be posed by morphologic patterns that overlap strikingly with primary ovarian neoplasms, benign, borderline, and malignant, as discussed herein.
  • [MeSH-major] Adenocarcinoma / pathology. Bile Duct Neoplasms / pathology. Gallbladder Neoplasms / pathology. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18580314.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


93. McKenney JK, Soslow RA, Longacre TA: Ovarian mature teratomas with mucinous epithelial neoplasms: morphologic heterogeneity and association with pseudomyxoma peritonei. Am J Surg Pathol; 2008 May;32(5):645-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian mature teratomas with mucinous epithelial neoplasms: morphologic heterogeneity and association with pseudomyxoma peritonei.
  • The morphologic, immunohistochemical, and clinical features of 42 patients with mucinous epithelial tumors arising in association with mature ovarian teratomas were evaluated.
  • Using the 2003 World Health Organization criteria for ovarian intestinal type mucinous neoplasms, 17 (40%) were classified as mucinous cystadenoma, 16 (38%) as intestinal-type mucinous epithelial neoplasm of low malignant potential (IM-LMP), 4 (10%) as intraepithelial carcinoma (IEC), and 5 (12%) as invasive mucinous carcinoma.
  • Of the 42 total cases, 55% had pseudomyxoma ovarii and 24% had classic PMP (1 cystadenoma, 6 IM-LMP, and 3 invasive carcinomas), whereas 5% had more localized accumulations of peritoneal mucin (both IM-LMP).
  • Pathologic evaluation of the peritoneum in these 12 cases revealed 6 with acellular mucin alone, 3 with low-grade mucinous epithelium (all 3 with ovarian IM-LMP), and 3 with high-grade mucinous carcinomatosis (all 3 with ovarian mucinous adenocarcinoma).
  • The only adverse outcomes occurred in the 3 patients with ovarian carcinoma and associated peritoneal carcinomatosis.
  • We report that a significant proportion of mucinous tumors associated with mature ovarian teratomas present with clinical PMP, which in most cases is associated with IM-LMP.
  • Ovarian teratoma-associated benign and IM-LMP mucinous neoplasms with microscopic peritoneal low-grade mucinous epithelium do not seem to be at significant risk for intra-abdominal recurrence, but numbers are few and follow-up is limited.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Ovarian Neoplasms / pathology. Peritoneal Neoplasms / pathology. Pseudomyxoma Peritonei / pathology. Teratoma / pathology


94. Artini PG, Ruggiero M, Monteleone P, Carpi A, Cristello F, Cela V, Genazzani AR: Vascular endothelial growth factor and its soluble receptor in benign and malignant ovarian tumors. Biomed Pharmacother; 2008 Jul-Aug;62(6):373-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vascular endothelial growth factor and its soluble receptor in benign and malignant ovarian tumors.
  • An imbalance between pro-angiogenic and anti-angiogenic factors is hypothesized in the pathogenesis of ovarian cystic disease.
  • The aim of the following study was to explore the possible role of free vascular endothelial growth factor receptor 1 (sVEGFR-1), a soluble regulator of vascular endothelial growth factor (VEGF) action, in ovarian cystoadenoma, endometriomata and cystoadenocarcinoma.
  • Forty-eight women, of whom fourteen had ovarian serous cysts, twenty-eight had stage III-IV ovarian endometriomata, and six had stage IIIB-IIIC ovarian carcinoma, were included.
  • Sampling of serum, peritoneal and ovarian cystic fluids and of tumor tissue was performed before, during and following surgery, respectively.
  • Western blot evidenced a marked expression of VEGF and soluble VEGFR-1 in endometriosis tissue with respect to benign cyst tissue but a lower expression of both molecules, contrary to that expected, in cancer tissue.
  • In conclusion, all in all, our data indicate that an excess of local VEGF with respect to its soluble receptor VEGFR-1 may be a key factor in the onset and maintenance of pathological neo-angiogenesis in ovarian cyst formation.
  • [MeSH-major] Ovarian Diseases / metabolism. Ovarian Neoplasms / metabolism. Vascular Endothelial Growth Factor A / metabolism. Vascular Endothelial Growth Factor Receptor-1 / metabolism
  • [MeSH-minor] Adult. Aged. Ascitic Fluid / chemistry. Cyst Fluid / chemistry. Cystadenocarcinoma / metabolism. Cystadenoma / metabolism. Endometriosis / metabolism. Female. Gene Expression. Humans. Middle Aged. Neoplasm Staging. Neovascularization, Pathologic / physiopathology. Ovarian Cysts / metabolism. Ovarian Cysts / physiopathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Disorders.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18037256.001).
  • [ISSN] 0753-3322
  • [Journal-full-title] Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie
  • [ISO-abbreviation] Biomed. Pharmacother.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Vascular Endothelial Growth Factor A; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-1
  •  go-up   go-down


95. Wang L, Chang X, Yuan G, Zhao Y, Wang P: Expression of peptidylarginine deiminase type 4 in ovarian tumors. Int J Biol Sci; 2010;6(5):454-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of peptidylarginine deiminase type 4 in ovarian tumors.
  • The current study focused on the expression of PADI4 in various subtypes of ovary cancers, and this study investigated the effects of estrogen on PADI4 expression in SKOV-3 cells that originated from ovary tumors.
  • However, PADI4 was either not detected or detected at low levels in granulosa cell tumor (n=6), malignant thecoma (n=6), ovarian cystadenoma (n=5) and normal ovarian tissue (n=11).
  • Real-time PCR and western blot analyses confirmed that PADI4 was expressed at higher levels in ovarian adenocarcinoma (n=8) compared to ovarian cystadenoma (n=5) (p< 0.05).
  • The results suggest an important role for PADI4 in the tumorigenesis of ovary cancers that are under the regulation of estrogen.
  • [MeSH-major] Hydrolases / metabolism. Ovarian Neoplasms / enzymology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. ESTRADIOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Endocr Rev. 1998 Aug;19(4):397-428 [9715373.001]
  • [Cites] J Biol Chem. 2008 Jul 18;283(29):20060-8 [18499678.001]
  • [Cites] Int Immunol. 1998 Dec;10(12):1891-5 [9885910.001]
  • [Cites] Clin Endocrinol (Oxf). 1998 Dec;49(6):695-707 [10209555.001]
  • [Cites] Rheumatology (Oxford). 2005 Jan;44(1):40-50 [15466895.001]
  • [Cites] Endocrine. 2005 Apr;26(3):297-300 [16034185.001]
  • [Cites] BMC Cancer. 2009;9:40 [19183436.001]
  • [Cites] J Leukoc Biol. 2001 Jul;70(1):46-51 [11435484.001]
  • [Cites] Biochem Biophys Res Commun. 2002 Jan 25;290(3):979-83 [11798170.001]
  • [Cites] Oncologist. 2002;7(1):73-81 [11854549.001]
  • [Cites] Nucleic Acids Res. 2001 May 1;29(9):e45 [11328886.001]
  • [Cites] J Biol Chem. 2002 Dec 20;277(51):49562-8 [12393868.001]
  • [Cites] J Clin Oncol. 2003 Mar 15;21(6):1180-9 [12637488.001]
  • [Cites] Ann Rheum Dis. 2004 Apr;63(4):373-81 [15020330.001]
  • [Cites] Cell. 2004 Sep 3;118(5):545-53 [15339660.001]
  • [Cites] Science. 2004 Oct 8;306(5694):279-83 [15345777.001]
  • [Cites] Acta Radiol Oncol. 1980;19(4):241-4 [6257044.001]
  • [Cites] Cancer Surv. 1994;19-20:287-307 [7895220.001]
  • [Cites] Am J Epidemiol. 1995 May 1;141(9):828-35 [7717359.001]
  • [Cites] Mol Carcinog. 2006 Mar;45(3):183-96 [16355400.001]
  • [Cites] Apoptosis. 2006 Feb;11(2):183-96 [16502257.001]
  • [Cites] Mol Endocrinol. 2007 Jul;21(7):1617-29 [17456793.001]
  • [Cites] Hum Reprod Update. 2007 Sep-Oct;13(5):453-63 [17573406.001]
  • [Cites] Gynecol Oncol. 2007 Nov;107(2):266-73 [17698176.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10746-50 [9724775.001]
  • (PMID = 20827398.001).
  • [ISSN] 1449-2288
  • [Journal-full-title] International journal of biological sciences
  • [ISO-abbreviation] Int. J. Biol. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / RNA, Messenger; 4TI98Z838E / Estradiol; EC 3.- / Hydrolases; EC 3.5.3.15 / peptidylarginine deiminase type IV
  • [Other-IDs] NLM/ PMC2935668
  • [Keywords] NOTNLM ; Peptidylarginine deiminase type 4 (PADI4/PAD4) / estrodial-17β. / ovarian cancer (OCa)
  •  go-up   go-down


96. Takaori K, Hruban RH, Maitra A, Tanigawa N: Current topics on precursors to pancreatic cancer. Adv Med Sci; 2006;51:23-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mucinous cystic neoplasms (MCNs), intraductal papillary mucinous neoplasms (IPMNs), and pancreatic intraepithelial neoplasias (PanINs) all harbor varying degrees of dysplasia and stepwise accumulation of genetic alterations, suggesting progression of these lesions from benign toward malignant neoplasms.
  • MCNs have a characteristic ovarian-type stroma.
  • [MeSH-minor] Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Carcinoma, Pancreatic Ductal / metabolism. Carcinoma, Pancreatic Ductal / pathology. Carcinoma, Papillary / metabolism. Carcinoma, Papillary / pathology. Cystadenoma, Mucinous / metabolism. Cystadenoma, Mucinous / pathology. Disease Progression. Humans. Models, Biological. Tumor Suppressor Protein p53 / analysis

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17357272.001).
  • [ISSN] 1896-1126
  • [Journal-full-title] Advances in medical sciences
  • [ISO-abbreviation] Adv Med Sci
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53
  • [Number-of-references] 81
  •  go-up   go-down


97. Makarla PB, Saboorian MH, Ashfaq R, Toyooka KO, Toyooka S, Minna JD, Gazdar AF, Schorge JO: Promoter hypermethylation profile of ovarian epithelial neoplasms. Clin Cancer Res; 2005 Aug 1;11(15):5365-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Promoter hypermethylation profile of ovarian epithelial neoplasms.
  • PURPOSE: Ovarian carcinomas are believed to arise de novo from surface epithelium, but the actual molecular pathogenesis is unknown.
  • The aim of this study was to compare the promoter hypermethylation profiles of ovarian epithelial neoplasms to better understand the role of epigenetic silencing in carcinogenesis.
  • EXPERIMENTAL DESIGN: We analyzed the DNA promoter methylation status of eight tumor suppressor and cancer-related genes (p16, RARbeta, E-cadherin,H-cadherin, APC, GSTP1, MGMT, RASSF1A) in 23 benign cystadenomas, 23 low malignant potential (LMP) tumors, and 23 invasive carcinomas by methylation-specific PCR.
  • RESULTS: Benign cystadenomas exhibited promoter hypermethylation in only two genes, p16 (13%) and E-cadherin (13%).
  • CONCLUSIONS: Promoter hypermethylation is a frequent epigenetic event that occurs most commonly in invasive epithelial ovarian carcinomas.
  • The profile of aberrant methylation suggests that an accumulation of events at specific genes may trigger malignant transformation of some benign cystadenomas and LMP tumors.
  • [MeSH-major] DNA Methylation. Neoplasms, Glandular and Epithelial / genetics. Ovarian Neoplasms / genetics. Promoter Regions, Genetic
  • [MeSH-minor] Adenomatous Polyposis Coli Protein / genetics. Adult. Aged. Aged, 80 and over. Cadherins / genetics. Carcinoma / genetics. Carcinoma / pathology. Cell Transformation, Neoplastic. Cyclin-Dependent Kinase Inhibitor p16 / genetics. Cystadenoma / genetics. DNA / metabolism. Epigenesis, Genetic. Female. Gene Silencing. Glutathione S-Transferase pi / genetics. Humans. Middle Aged. Neoplasm Invasiveness. Neoplasm Metastasis. O(6)-Methylguanine-DNA Methyltransferase / genetics. Polymerase Chain Reaction. Receptors, Retinoic Acid / genetics. Tumor Suppressor Proteins / genetics

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16061849.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adenomatous Polyposis Coli Protein; 0 / Cadherins; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / H-cadherin; 0 / RASSF1 protein, human; 0 / Receptors, Retinoic Acid; 0 / Tumor Suppressor Proteins; 0 / retinoic acid receptor beta; 9007-49-2 / DNA; EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase; EC 2.5.1.18 / GSTP1 protein, human; EC 2.5.1.18 / Glutathione S-Transferase pi
  •  go-up   go-down


98. Rodabaugh KJ, Mhawech-Fauceglia P, Groth J, Lele S, Sood AK: Prostate-derived Ets factor is overexpressed in serous epithelial ovarian tumors. Int J Gynecol Pathol; 2007 Jan;26(1):10-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prostate-derived Ets factor is overexpressed in serous epithelial ovarian tumors.
  • The frequent overexpression of prostate-derived Ets factor (PDEF) mRNA in ovarian cancer has been previously reported.
  • The aim of this study was to evaluate PDEF protein expression in ovarian cancer and how this expression might vary at different stages of epithelial ovarian tumors in comparison to normal ovary.
  • A new rabbit polyclonal antibody to PDEF was prepared, and immunohistochemistry was performed on tissue sections from 12 normal ovaries, 10 cases of benign serous cystadenoma, 17 cases of low malignant potential tumor, 19 cases of stage 1, and 15 cases of advanced stage primary epithelial (serous) ovarian carcinomas and their peritoneal metastases.
  • All 12 normal ovary and 10 benign serous cystadenoma cases were negative for PDEF expression.
  • In contrast, 6 of 17 (35%) low malignant potential tumors, 5 of 19 (27%) stage 1, and 5 of 15 (33%) advanced stage ovarian tumors stained positive for PDEF expression.
  • Together, these results show frequent overexpression of PDEF protein in epithelial ovarian tumors and its lack of expression in normal ovary and cystadenomas, and this supports a role for PDEF in ovarian tumorigenesis.
  • Furthermore, these results suggest that PDEF is a potential marker and target in ovarian cancer.
  • [MeSH-major] Cystadenocarcinoma, Serous / metabolism. Neoplasms, Glandular and Epithelial / metabolism. Ovarian Neoplasms / metabolism. Proto-Oncogene Proteins c-ets / metabolism
  • [MeSH-minor] Amino Acids / immunology. Animals. Antibodies / immunology. Biomarkers, Tumor / metabolism. Cell Line, Tumor. Female. Humans. Neoplasm Staging. Ovary / metabolism. Peptide Fragments / immunology. Rabbits

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Int J Gynecol Pathol. 2007 Apr;26(2):205
  • (PMID = 17197890.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30CA16056; United States / NCI NIH HHS / CA / R 41 CA84167
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Amino Acids; 0 / Antibodies; 0 / Biomarkers, Tumor; 0 / Peptide Fragments; 0 / Proto-Oncogene Proteins c-ets; 0 / SPDEF protein, human
  •  go-up   go-down


99. Brustmann H: Poly(adenosine diphosphate-ribose) polymerase expression in serous ovarian carcinoma: correlation with p53, MIB-1, and outcome. Int J Gynecol Pathol; 2007 Apr;26(2):147-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Poly(adenosine diphosphate-ribose) polymerase expression in serous ovarian carcinoma: correlation with p53, MIB-1, and outcome.
  • This study investigated the expression of poly(adenosine diphosphate-ribose) polymerase (PARP) in a cohort of ovarian serous carcinomas by immunohistochemistry with regard to outcome, clinicopathologic parameters, proliferation as assessed by MIB-1 labeling indices (LIs), and p53 immunoexpression.
  • Formalin-fixed, paraffin-embedded archival tissues of 50 ovarian serous carcinomas were immunostained with antibodies to PARP, MIB-1, and p53.
  • In addition, 10 benign serous cystadenomas and 10 typical serous borderline ovarian tumors were included in the PARP immunostudy.
  • The expression of PARP was scored negative in all serous cystadenomas and low in serous borderline ovarian tumors.
  • Strong PARP expression was determined in 38 cases (76%), and low expression in 12 cases (12%) of ovarian serous carcinomas; MIB-1 staining was noted in all cases (mean, 44.2; range, 10.8-66.5), positivity for p53 in 39 cases (78%).
  • This study indicates that PARP expression is frequently upregulated in ovarian serous carcinomas, related with MIB-1 LIs and p53 expression, and may serve as a marker of aggressive behavior with prognostic value.
  • [MeSH-major] Cystadenoma, Serous / enzymology. Ki-67 Antigen / metabolism. Ovarian Neoplasms / enzymology. Poly(ADP-ribose) Polymerases / metabolism. Tumor Suppressor Protein p53 / metabolism

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17413981.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53; EC 2.4.2.30 / Poly(ADP-ribose) Polymerases
  •  go-up   go-down


100. Adsay NV: Cystic neoplasia of the pancreas: pathology and biology. J Gastrointest Surg; 2008 Mar;12(3):401-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In contrast with solid tumors, most of which are invasive ductal adenocarcinoma with dismal prognosis, cystic lesions of the pancreas are often either benign or low-grade indolent neoplasia.
  • While many are innocuous adenomas--in particular, those that are small and less complex, and in the case of IPMN, those that are branch-duct type are more commonly benign, some harbor or progress into in situ or invasive carcinomas.
  • The presence of ovarian-type stroma has now almost become a requirement for the diagnosis of MCN, and when defined as such, MCN is seen almost exclusively in women of perimenopausal age group as thick-walled multilocular cystic mass in the tail of the pancreas in contrast with IPMN which afflicts an elder population, both genders in almost equal numbers, and occur predominantly in the head of the organ.
  • In conclusion, cystic lesions in the pancreas constitute a biologically and pathologically diverse category most (but not all) of which are either benign or treatable diseases; however, a substantial subset, especially mucinous ones, has malignant potential that requires careful analysis.
  • [MeSH-minor] Adenocarcinoma, Mucinous / mortality. Adenocarcinoma, Mucinous / pathology. Carcinoma, Pancreatic Ductal / pathology. Carcinoma, Papillary / mortality. Carcinoma, Papillary / pathology. Cystadenoma / pathology. Cystadenoma, Serous / pathology. Dilatation, Pathologic. Humans. Necrosis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2004 Aug;28(8):977-87 [15252303.001]
  • [Cites] Am J Surg Pathol. 1989 Jan;13(1):61-6 [2909198.001]
  • [Cites] Ann Surg. 2004 Jun;239(6):788-97; discussion 797-9 [15166958.001]
  • [Cites] Semin Diagn Pathol. 2000 Feb;17(1):81-8 [10721809.001]
  • [Cites] Br J Surg. 2003 Oct;90(10):1244-9 [14515294.001]
  • [Cites] Pancreatology. 2006;6(1-2):17-32 [16327281.001]
  • [Cites] Semin Diagn Pathol. 2000 Feb;17(1):43-55 [10721806.001]
  • [Cites] Am J Surg Pathol. 1999 Apr;23 (4):410-22 [10199470.001]
  • [Cites] J Gastrointest Surg. 2003 Mar-Apr;7(3):417-28 [12654569.001]
  • [Cites] Virchows Arch. 2004 Aug;445(2):168-78 [15185076.001]
  • [Cites] Semin Diagn Pathol. 2000 Feb;17(1):56-65 [10721807.001]
  • [Cites] Am J Surg Pathol. 2004 Jul;28(7):839-48 [15223952.001]
  • [Cites] Am J Surg Pathol. 2000 Oct;24(10):1372-7 [11023098.001]
  • [Cites] Am J Surg Pathol. 1999 Jan;23 (1):1-16 [9888699.001]
  • [Cites] Semin Diagn Pathol. 2000 Feb;17(1):66-80 [10721808.001]
  • [Cites] Mod Pathol. 2007 Feb;20 Suppl 1:S71-93 [17486054.001]
  • [Cites] World J Surg. 2003 Mar;27(3):319-23 [12607059.001]
  • [Cites] Am J Surg Pathol. 2001 Jan;25(1):26-42 [11145249.001]
  • [Cites] Am J Clin Pathol. 1978 Mar;69(3):289-98 [637043.001]
  • (PMID = 17957438.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 19
  •  go-up   go-down






Advertisement